Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
49.5 /100
Rank 7 out of 27 Sectors -
Advance/Decline
310/347
-
No. of Companies657
-
Avg. Market Cap7,779
-
Price to Earning Ratio6.76
-
Price to Earning Growth Ratio0.74
-
Price to Book Ratio29.90
-
Return on Equity47.26
-
Return on Capital Employed-
-
Return on Assets10.76
-
Dividend yield 1 year %0.77 %
-
Net Profit Growth Annual YoY %-11.97 %
-
Net Profit Growth Qtr YoY %-62.69 %
-
Net Profit Growth Qtr QoQ %-70.04 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
389,142.7
|
220.2
|
L
 -4.0%
H
217.9
227.2
|
L
 -4.6%
H
217.9
231.2
|
L
 -2.6%
H
217.9
232.0
|
L
 -5.9%
H
211.7
239.3
|
L
 22%
H
164.4
244.8
|
L
 34.7%
H
131.0
244.8
|
L
 106.7%
H
101.8
244.8
|
L
 283.8%
H
50.7
244.8
|
| Adc Therapeutics SA |
|
441.0
|
3.6
|
L
 1.1%
H
3.4
3.7
|
L
 1.7%
H
3.4
3.7
|
L
 8.2%
H
3.2
4.3
|
L
 -12.8%
H
2.9
4.8
|
L
 76.2%
H
1.1
4.8
|
L
 2.3%
H
0.4
6.0
|
L
 -88.1%
H
0.4
34.5
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
3,995.6
|
12.7
|
L
 0.4%
H
12.3
12.8
|
L
 -1.6%
H
12.3
13.0
|
L
 4.4%
H
11.8
13.0
|
L
 22.3%
H
9.6
13.0
|
L
 62.5%
H
6.7
13.0
|
L
 480.4%
H
1.2
13.0
|
L
 158.3%
H
1.2
13.0
|
L
 -70.2%
H
1.2
43.2
|
| Annovis Bio Inc |
|
100.7
|
3.8
|
L
 4.1%
H
3.6
3.8
|
L
 8.6%
H
3.3
3.8
|
L
 -16.5%
H
3.3
4.6
|
L
 71.2%
H
1.6
5.5
|
L
 -29.5%
H
1.1
5.6
|
L
 -71.1%
H
1.1
23.9
|
L
 -56.4%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,741.8
|
7.4
|
L
 2.6%
H
7.2
7.6
|
L
 3.8%
H
6.9
7.6
|
L
 6.8%
H
6.7
7.6
|
L
 10.8%
H
5.9
7.6
|
L
 -5.1%
H
4.3
8.7
|
L
 3.4%
H
4.0
11.5
|
L
 -66.1%
H
4.0
34.8
|
L
 -92.7%
H
4.0
105.9
|
| Bristol-Myers Squibb |
|
108,017.1
|
53.1
|
L
 -0.8%
H
52.1
53.4
|
L
 -1.9%
H
52.1
54.4
|
L
 1.7%
H
50.3
55.0
|
L
 16.7%
H
42.5
55.0
|
L
 -6.2%
H
42.5
63.3
|
L
 -26.2%
H
39.4
75.2
|
L
 -13.8%
H
39.4
81.4
|
L
 -22.4%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
674.9
|
12.9
|
L
 2.7%
H
12.4
13.0
|
L
 5.2%
H
12.0
13.0
|
L
 8.0%
H
11.2
13.0
|
L
 40.4%
H
8.9
13.4
|
L
 26.2%
H
4.0
13.4
|
L
 4.0%
H
1.4
16.7
|
L
 -86.8%
H
1.4
127.2
|
L
 -64.7%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,452.7
|
23.1
|
L
 2.4%
H
22.3
23.1
|
L
 1.8%
H
22
23.1
|
L
 5.3%
H
20.4
23.1
|
L
 11.7%
H
19.5
23.7
|
L
 92.4%
H
8.0
23.7
|
L
 85.1%
H
7.9
23.7
|
L
 -24.7%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
98,876.4
|
49.0
|
L
 -1.2%
H
48.6
49.6
|
L
 -0.1%
H
48.6
49.6
|
L
 0.9%
H
47.2
49.6
|
L
 13.1%
H
42.8
49.6
|
L
 46.5%
H
31.7
49.6
|
L
 39.9%
H
31.7
49.6
|
L
 27.6%
H
28.5
49.6
|
L
 19.0%
H
28.5
49.6
|
| Johnson & Johnson |
|
492,243.1
|
204.3
|
L
 -1.5%
H
200.9
205.9
|
L
 -1.6%
H
200.9
209.5
|
L
 0.9%
H
199.9
215.2
|
L
 8.3%
H
182.9
215.2
|
L
 41.7%
H
140.7
215.2
|
L
 13.4%
H
140.7
215.2
|
L
 30.5%
H
140.7
215.2
|
L
 103.3%
H
94.3
215.2
|
| Eli Lilly |
|
932,171.0
|
1,041.5
|
L
 -3.6%
H
1033.4
1085.4
|
L
 -3.4%
H
1033.4
1085.5
|
L
 2.7%
H
977.1
1088.5
|
L
 24.0%
H
783.8
1112.0
|
L
 33.6%
H
623.8
1112.0
|
L
 186.8%
H
302.1
1112.0
|
L
 529.3%
H
161.8
1112.0
|
L
 1156.8%
H
64.2
1112.0
|
| Merck & Company |
|
266,668.5
|
107.4
|
L
 0.9%
H
105.8
108.4
|
L
 0.6%
H
104.4
108.4
|
L
 6.5%
H
96.1
108.4
|
L
 20.5%
H
82.0
108.4
|
L
 8.4%
H
73.3
108.4
|
L
 -4.1%
H
73.3
134.6
|
L
 39.1%
H
68.4
134.6
|
L
 114.5%
H
45.8
134.6
|
| Nuvation Bio Inc (Class A) |
|
2,944.9
|
8.6
|
L
 0.1%
H
8.0
8.6
|
L
 -8.6%
H
8.0
9.4
|
L
 3.4%
H
7.8
9.8
|
L
 131.5%
H
3.4
9.8
|
L
 215.8%
H
1.5
9.8
|
L
 311.0%
H
1.0
9.8
|
L
 -23.3%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
244,880.1
|
55.1
|
L
 5.2%
H
53.4
55.4
|
L
 5.2%
H
50.6
55.4
|
L
 14.8%
H
46.1
55.4
|
L
 -7.6%
H
43.1
60.9
|
L
 -37.1%
H
43.1
93.8
|
L
 -19.4%
H
43.1
148.2
|
L
 54.3%
H
33.3
148.2
|
L
 92.4%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
264,620.6
|
137.9
|
L
 -0.5%
H
135.6
138.0
|
L
 -0.9%
H
135.6
139.5
|
L
 4.1%
H
130.0
140.2
|
L
 4.2%
H
121.6
140.2
|
L
 41.2%
H
97.4
140.2
|
L
 50.2%
H
80.0
140.2
|
L
 46.1%
H
74.1
140.2
|
L
 81.9%
H
59.2
140.2
|
| Organon & Co. |
|
1,934.3
|
7.4
|
L
 2.8%
H
7.2
7.8
|
L
 3.6%
H
7.0
7.8
|
L
 4.2%
H
6.8
7.8
|
L
 -32.4%
H
6.2
11.1
|
L
 -51.8%
H
6.2
17.2
|
L
 -74.3%
H
6.2
32.4
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare Inc |
|
3,003.8
|
62.5
|
L
 2.0%
H
60.9
63.5
|
L
 -0.6%
H
60.2
63.9
|
L
 4.0%
H
59.5
63.9
|
L
 -2.3%
H
57.3
64.1
|
L
 -18.7%
H
57.3
90.0
|
L
 -3.6%
H
56.0
90.0
|
L
 72.8%
H
36.1
90.0
|
L
 26.0%
H
26.3
90.0
|
| Pfizer |
|
143,109.3
|
25.2
|
L
 0.0%
H
25.0
25.4
|
L
 0.3%
H
24.8
25.4
|
L
 -2.1%
H
24.8
26.7
|
L
 -8.0%
H
23.9
27.4
|
L
 -5.4%
H
20.9
27.7
|
L
 -49.8%
H
20.9
51.6
|
L
 -31.6%
H
20.9
61.7
|
L
 -16.8%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,950.1
|
14.2
|
L
 2.0%
H
13.9
14.6
|
L
 2.5%
H
13.6
14.6
|
L
 5.0%
H
12.7
14.6
|
L
 -37.1%
H
12.2
22.5
|
L
 -45.4%
H
12.2
30.9
|
L
 -60.0%
H
12.2
40.3
|
L
 -68.3%
H
12.2
50.9
|
L
 -90.1%
H
12.2
152.4
|
| Arcus Biosciences Inc |
|
2,693.6
|
21.8
|
L
 -6.5%
H
20.6
23.4
|
L
 -5.7%
H
20.6
24.2
|
L
 -13.8%
H
20.4
26.4
|
L
 63.1%
H
13.6
26.4
|
L
 44.6%
H
6.5
26.4
|
L
 6.8%
H
6.5
26.4
|
L
 -16.8%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,505.5
|
13.8
|
L
 -0.3%
H
13.7
13.9
|
L
 -2.4%
H
13.7
14.2
|
L
 -2.3%
H
13.6
14.3
|
L
 -2.4%
H
13.1
15.0
|
L
 -10.5%
H
12.3
16.2
|
L
 32.8%
H
10.2
74.9
|
L
 -2.9%
H
9.6
74.9
|
L
 51.4%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
49,567.7
|
15.7
|
L
 0.5%
H
15.5
15.7
|
L
 0.3%
H
15.5
15.8
|
L
 9.9%
H
14.2
15.8
|
L
 7.5%
H
13.0
15.8
|
L
 18.3%
H
12.8
15.8
|
L
 0.6%
H
12.6
17.2
|
L
 -12.8%
H
12.3
20.0
|
L
 -36.7%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
35,565.8
|
31
|
L
 0.2%
H
30.5
31.1
|
L
 -2.8%
H
30.5
31.7
|
L
 9.1%
H
28
32.0
|
L
 54.9%
H
18.8
32.0
|
L
 46.0%
H
12.5
32.0
|
L
 209.4%
H
7.1
32.0
|
L
 199.8%
H
6.8
32.0
|
L
 -52.5%
H
6.1
65.9
|
| Usana Health Sciences Inc |
|
347.5
|
19.0
|
L
 -2.2%
H
18.9
19.6
|
L
 -4.2%
H
18.9
20.0
|
L
 -3.1%
H
18.9
21.1
|
L
 -30.0%
H
18.5
27.3
|
L
 -47.4%
H
18.5
38.3
|
L
 -65.3%
H
18.5
69.6
|
L
 -75.6%
H
18.5
107.9
|
L
 -70.1%
H
18.5
138.0
|
| Zoetis (Class A) |
|
57,012.5
|
129.4
|
L
 2.7%
H
125.4
129.9
|
L
 2.5%
H
124.0
129.9
|
L
 7.4%
H
115.6
129.9
|
L
 -11.6%
H
115.3
148.3
|
L
 -20.8%
H
115.3
177.4
|
L
 -13.2%
H
115.3
201.9
|
L
 -20.9%
H
115.3
249.3
|
L
 173.7%
H
38.3
249.3
|
| Biohaven Ltd |
|
1,317.6
|
9.9
|
L
 -8.4%
H
9.6
10.9
|
L
 -10.9%
H
9.6
11.7
|
L
 3.3%
H
9.3
11.8
|
L
 -37.2%
H
7.5
18.6
|
L
 -74.3%
H
7.5
44.3
|
L
 -32.2%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
119.2
|
2.5
|
L
 3.7%
H
2.5
2.6
|
L
 -5.2%
H
2.4
2.7
|
L
 -1.2%
H
2.2
2.9
|
L
 29.1%
H
1.9
3.8
|
L
 -22.4%
H
1.4
3.8
|
L
 -80.0%
H
1.2
13.5
|
L
 -83.9%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,026.7
|
3.4
|
L
H
3.4
3.6
|
L
 -4.2%
H
3.3
3.6
|
L
 -6.0%
H
3.3
3.9
|
L
 -41.9%
H
3.3
6.5
|
L
 11%
H
1.9
6.5
|
L
 -63.4%
H
1.9
11.4
|
L
 -91.2%
H
1.9
55.2
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
282.9
|
5.2
|
L
 -1.7%
H
5.1
5.4
|
L
 -4.2%
H
5.1
5.5
|
L
 7.2%
H
4.8
5.6
|
L
 -3.5%
H
4
5.7
|
L
 -13.3%
H
3.9
7.5
|
L
 70.6%
H
2.2
9.0
|
L
 -87.6%
H
2.2
94.8
|
L
 -93.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,301.2
|
26.9
|
L
 -4.9%
H
25.2
28.1
|
L
 -15.2%
H
25.2
31.8
|
L
 -13.1%
H
25.2
32.6
|
L
 35.8%
H
19.7
32.6
|
L
 29.2%
H
5.5
32.6
|
L
 -9.3%
H
2.2
53.9
|
L
 -46.2%
H
2.2
66
|
L
 -97.3%
H
2.2
1062.7
|
| Acumen Pharma Inc |
|
119.9
|
2.0
|
L
 -2.0%
H
1.9
2.1
|
L
 -6.2%
H
1.9
2.1
|
L
H
1.9
2.4
|
L
 14.5%
H
1.5
2.5
|
L
 4.2%
H
0.9
2.5
|
L
 -63.7%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
905.8
|
4.7
|
L
 -1.3%
H
4.7
4.8
|
L
 -1.5%
H
4.6
5.1
|
L
 6.8%
H
4.3
5.1
|
L
 7.5%
H
4.1
5.1
|
L
 37.7%
H
2.7
5.1
|
L
 108.4%
H
1.7
5.1
|
L
 29.4%
H
1.7
6.5
|
L
 4.2%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
57.1
|
2.4
|
L
 7.3%
H
2.2
2.4
|
L
 -3.3%
H
2.1
2.5
|
L
 -7.1%
H
2.0
2.6
|
L
 -21.7%
H
2.0
3.4
|
L
 256.1%
H
0.4
5.5
|
L
 -62.1%
H
0.4
18.7
|
L
 -95.3%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
| Acadia Pharma Inc |
|
4,424.1
|
26.2
|
L
 -0.5%
H
25.6
26.6
|
L
 -5.3%
H
25.6
27.6
|
L
 -1.5%
H
25.6
28.4
|
L
 20.0%
H
19.7
28.4
|
L
 39.9%
H
13.4
28.4
|
L
 52.9%
H
13.4
33.9
|
L
 -50.5%
H
12.2
55.9
|
L
 -24.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
78.2
|
8.2
|
L
 -7.6%
H
7.9
9.1
|
L
 -2.0%
H
7.6
9.1
|
L
 -8.2%
H
7.4
9.4
|
L
 -39%
H
7.4
17.4
|
L
 -53.9%
H
7.2
17.4
|
L
 -94.0%
H
7.2
152.4
|
L
 -96.2%
H
7.2
349.9
|
L
H
7.2
349.9
|
| Achieve Life Sciences Inc |
|
276.3
|
5.2
|
L
 4.4%
H
4.9
5.3
|
L
 15.9%
H
4.3
5.3
|
L
 8.6%
H
4.2
5.3
|
L
 64.8%
H
3.0
5.8
|
L
 40.3%
H
1.8
5.8
|
L
 108.4%
H
1.8
10.3
|
L
 -34.3%
H
1.8
16.1
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
354.1
|
3.5
|
L
 4.8%
H
3.3
3.6
|
L
 12.5%
H
3.1
3.6
|
L
 22.2%
H
2.5
3.8
|
L
 -11.8%
H
2.5
4
|
L
 18.1%
H
1.4
4
|
L
 61.5%
H
1.4
5.1
|
L
 -33.8%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
3,575.2
|
61.8
|
L
 -2.4%
H
60.4
63.1
|
L
 -5.9%
H
60.4
66.0
|
L
 -9.7%
H
60.4
79.8
|
L
 -27.3%
H
60.4
94.1
|
L
 -21.9%
H
47.9
94.1
|
L
 90.7%
H
26.3
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Aclaris Therapeutics Inc |
|
287.1
|
2.7
|
L
 -8.0%
H
2.6
2.9
|
L
 -12.5%
H
2.6
3.0
|
L
 -12.0%
H
2.6
3.5
|
L
 42.5%
H
1.7
3.5
|
L
 1.9%
H
1.1
3.5
|
L
 -82.3%
H
0.6
18.5
|
L
 -59.1%
H
0.6
30.4
|
L
 -90.0%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
72.3
|
2.3
|
L
 -6.9%
H
2.3
2.5
|
L
 -6.2%
H
2.3
2.6
|
L
 -5.0%
H
2.1
2.7
|
L
 19.9%
H
1.7
2.7
|
L
 -64.7%
H
1.1
8
|
L
 -81.0%
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
20.9
|
1.2
|
L
 6.0%
H
1.1
1.3
|
L
 11.8%
H
1.0
1.3
|
L
 -2.4%
H
1.0
1.3
|
L
 29.5%
H
1.0
1.6
|
L
 146%
H
0.4
1.6
|
L
 -42.8%
H
0.4
2.8
|
L
 -95.1%
H
0.4
58.8
|
L
 -98.4%
H
0.4
115
|
| Grace Therapeutics Inc |
|
56.2
|
3.6
|
L
 -0.8%
H
3.5
3.7
|
L
 6.8%
H
3.4
3.7
|
L
 10.7%
H
3.2
3.7
|
L
 20.2%
H
3.0
3.7
|
L
 -11.3%
H
1.8
4.7
|
L
 16.3%
H
1.7
5.1
|
L
 -80.9%
H
1.7
58.6
|
L
 -97.0%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.7
|
2.9
|
L
 3.6%
H
2.7
2.9
|
L
 -10.3%
H
2.4
3.2
|
L
 -17.8%
H
2.4
4.6
|
L
 -37.1%
H
2.4
8.3
|
L
 -83.9%
H
2.4
25
|
L
 -96.8%
H
2.4
176.4
|
L
H
2.4
176.4
|
L
H
2.4
176.4
|
| Adial Pharma Inc |
|
6.9
|
0.3
|
L
 8.3%
H
0.2
0.3
|
L
 13.0%
H
0.2
0.3
|
L
 -21.2%
H
0.2
0.3
|
L
 -35%
H
0.2
0.4
|
L
 -76.2%
H
0.2
1.3
|
L
 -95.8%
H
0.2
15
|
L
 -99.4%
H
0.2
127
|
L
H
0.2
236
|
| Adma Biologics Inc |
|
4,291.1
|
18.0
|
L
 0.8%
H
17.7
18.2
|
L
 -6.5%
H
17.5
19.4
|
L
 -10.3%
H
17.5
20.5
|
L
 23.0%
H
13.8
20.5
|
L
 -2.2%
H
13.5
25.7
|
L
 394.0%
H
2.9
25.7
|
L
 754.5%
H
1.0
25.7
|
L
 128.8%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,468.6
|
16.2
|
L
 1.6%
H
15.3
16.2
|
L
 -3.2%
H
15.3
16.8
|
L
 -7.4%
H
14.6
17.5
|
L
 12.5%
H
13.3
20.8
|
L
 124.6%
H
6.0
20.8
|
L
 101.9%
H
2.3
20.8
|
L
 -71.0%
H
2.3
71.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
1.7
|
1.0
|
L
 8.0%
H
0.9
1.0
|
L
 -15.2%
H
0.8
1.1
|
L
 -67.4%
H
0.8
3.8
|
L
 -98.9%
H
0.8
85.0
|
L
 -100.0%
H
0.8
438581.3
|
L
 -100.0%
H
0.8
3453280000
|
L
 -100.0%
H
0.8
10000000000
|
L
H
0.8
10000000000
|
| Agenus Inc |
|
109.5
|
3.2
|
L
 -0.3%
H
3.2
3.3
|
L
 -2.7%
H
3.0
3.3
|
L
 -20.7%
H
3.0
4.1
|
L
 -22.2%
H
3.0
4.7
|
L
 -2.7%
H
1.4
7.3
|
L
 -93.5%
H
1.4
196
|
L
 -94.9%
H
1.4
196
|
L
 -96.3%
H
1.4
196
|
| Agios Pharma Inc |
|
1,600.7
|
27.5
|
L
 1.0%
H
26.5
27.6
|
L
 -2.0%
H
26.5
28
|
L
 0.1%
H
24.2
30.0
|
L
 -32.2%
H
22.2
46
|
L
 -14.7%
H
22.2
46
|
L
 -4.9%
H
19.8
62.6
|
L
 -38.0%
H
16.8
62.6
|
L
 -56.9%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
121.3
|
30.0
|
L
 -2.0%
H
28
30.6
|
L
 -9.1%
H
28
33.3
|
L
 -10.6%
H
28
35.3
|
L
 88.6%
H
15.9
35.3
|
L
 97.4%
H
13.9
35.3
|
L
 169.9%
H
2.7
35.3
|
L
 -86%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Akebia Therapeutics Inc |
|
400.7
|
1.5
|
L
 -2.6%
H
1.5
1.6
|
L
 -9.0%
H
1.5
1.7
|
L
 -5.0%
H
1.5
1.7
|
L
 -46.6%
H
1.4
3.2
|
L
 -21.4%
H
1.4
4.1
|
L
 139.7%
H
0.5
4.1
|
L
 -48.3%
H
0.2
5.1
|
L
 -88.0%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
5.3
|
1.3
|
L
H
1.2
1.3
|
L
 -6.0%
H
1.2
1.4
|
L
 -14.4%
H
0.9
1.8
|
L
 -44.2%
H
0.9
2.5
|
L
 -64.6%
H
0.9
11.7
|
L
 -72.9%
H
0.2
11.7
|
L
 -88.8%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
255.1
|
4.2
|
L
 -9.2%
H
4.1
4.8
|
L
 -20.2%
H
4.1
5.3
|
L
 -13.1%
H
3.9
5.7
|
L
 -26.1%
H
3.9
5.8
|
L
 -21.5%
H
1.1
7.2
|
L
 -38.6%
H
1.1
12.0
|
L
 -35.1%
H
1.1
16.0
|
L
 -36.5%
H
1.1
16.7
|
| Alector Inc |
|
174.6
|
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 10.3%
H
1.4
1.6
|
L
 32.2%
H
1.2
1.6
|
L
 -51.8%
H
1.1
3.4
|
L
 -22.3%
H
0.9
3.4
|
L
 -82.8%
H
0.9
9.9
|
L
 -89.3%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
51.8
|
8.4
|
L
 -7.9%
H
8.3
10
|
L
 -16.8%
H
8.3
10
|
L
 -16.7%
H
8.3
13.7
|
L
 -16.5%
H
5.8
13.7
|
L
 -80.6%
H
3.8
46.3
|
L
 -64.2%
H
3.8
60.3
|
L
 -98.8%
H
3.8
937.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
4,623.3
|
28
|
L
 -0.9%
H
27.7
28.3
|
L
 -1.7%
H
27.6
28.6
|
L
 -4.4%
H
27.5
29.8
|
L
 -9.9%
H
27.5
36.3
|
L
 -4.1%
H
25.2
36.5
|
L
 10.5%
H
22.0
36.5
|
L
 41.8%
H
18.0
36.5
|
L
 -62.6%
H
12.0
76.8
|
| Allogene Therapeutics Inc |
|
303.4
|
1.4
|
L
H
1.3
1.4
|
L
 -2.2%
H
1.3
1.4
|
L
 -6.3%
H
1.3
1.6
|
L
 1.5%
H
1.0
1.6
|
L
 -37.5%
H
0.9
3.8
|
L
 -76.7%
H
0.9
8.4
|
L
 -94.8%
H
0.9
39.1
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
18.0
|
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 4.7%
H
1
1.2
|
L
 -3.5%
H
1.0
1.2
|
L
 -27.7%
H
1.0
1.8
|
L
 5.7%
H
0.6
2.1
|
L
 -100.0%
H
0.1
13157.2
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
52,558.8
|
397.8
|
L
 -0.6%
H
383.8
400
|
L
 -0.7%
H
383.8
407.2
|
L
 -14.5%
H
383.8
473.5
|
L
 -12.8%
H
383.8
495.6
|
L
 69.8%
H
205.9
495.6
|
L
 70.8%
H
142.0
495.6
|
L
 210.6%
H
117.6
495.6
|
L
 327.6%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
33.1
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 1.6%
H
1.0
1.3
|
L
 -9.4%
H
1.0
1.6
|
L
 5.9%
H
1.0
2.2
|
L
 -44.7%
H
1.0
3.5
|
L
 -50.6%
H
1.0
7.4
|
L
 -94%
H
1.0
46.6
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
426.8
|
4.1
|
L
 16.5%
H
4.0
4.5
|
L
 6.0%
H
3.5
4.5
|
L
 -23.0%
H
3.5
6.0
|
L
 4.6%
H
3.5
6.0
|
L
 -43.7%
H
2.9
7.8
|
L
 -72.4%
H
2.1
17.2
|
L
 -67.8%
H
2.1
24.6
|
L
 -99.3%
H
1.5
1050
|
| Alvotech |
|
1,526.8
|
4.9
|
L
 -2%
H
4.8
5.0
|
L
 -6.8%
H
4.8
5.2
|
L
 -3.4%
H
4.7
5.9
|
L
 -41.1%
H
4.3
9.0
|
L
 -63.1%
H
4.3
13.7
|
L
 -51.2%
H
4.3
18
|
L
H
4.3
18
|
L
H
4.3
18
|
| Kalaris Therapeutics Inc |
|
153.0
|
8.2
|
L
 -1.5%
H
7.9
8.9
|
L
 -11.7%
H
7.9
9.5
|
L
 38.2%
H
5.6
11.9
|
L
 23.2%
H
4.3
11.9
|
L
 1717.8%
H
0.4
12.9
|
L
 49.0%
H
0.4
12.9
|
L
 -79.4%
H
0.4
48.3
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
7.8
|
2.1
|
L
 7.9%
H
1.9
2.1
|
L
 1.5%
H
1.7
2.1
|
L
 -4.7%
H
1.7
2.3
|
L
 -19.0%
H
1.7
2.7
|
L
 -81.9%
H
1.7
11.7
|
L
 -99.7%
H
1.7
1071.9
|
L
H
1.7
45292.5
|
L
H
1.7
45292.5
|
| Amgen |
|
172,701.5
|
320.7
|
L
 -2.1%
H
318.2
326.5
|
L
 -3.7%
H
318.2
333.5
|
L
 -5.7%
H
312.4
340.9
|
L
 7.7%
H
288
346.4
|
L
 22.8%
H
257.1
346.4
|
L
 21.3%
H
211.7
346.9
|
L
 41.5%
H
198.6
346.9
|
L
 102.6%
H
133.6
346.9
|
| Amylyx Pharma Inc |
|
1,250.8
|
11.4
|
L
 -0.3%
H
10.8
11.5
|
L
 -7.6%
H
10.8
12.6
|
L
 -21.4%
H
10.8
15.1
|
L
 -15.1%
H
10.8
17.0
|
L
 174.5%
H
2.6
17.0
|
L
 -68.0%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,227.8
|
26.7
|
L
 1.0%
H
26.1
27.5
|
L
 -1.5%
H
26.0
27.5
|
L
 -1.6%
H
25.2
27.5
|
L
 -0.1%
H
22.9
29
|
L
 -26.4%
H
20.4
39.0
|
L
 -4.5%
H
20.4
67.7
|
L
 32.7%
H
16.9
67.7
|
L
 95.0%
H
10.5
67.7
|
| AnaptysBio Inc |
|
1,196.1
|
43.2
|
L
 -3.9%
H
42.8
44.7
|
L
 -13.8%
H
42.8
52.5
|
L
 -0.2%
H
42.8
52.5
|
L
 39.6%
H
29.5
52.5
|
L
 195.9%
H
12.2
52.5
|
L
 48.0%
H
12.2
52.5
|
L
 84.9%
H
12.2
52.5
|
L
H
10
134
|
| Anebulo Pharma Inc |
|
46.4
|
1.1
|
L
H
1.1
1.2
|
L
 0.9%
H
0.9
1.2
|
L
 -52.3%
H
0.9
2.4
|
L
 -51.1%
H
0.9
2.9
|
L
 -31.5%
H
0.9
3.4
|
L
 -53.3%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| ANI Pharma Inc |
|
1,766.6
|
78.7
|
L
 0.3%
H
76.9
79.1
|
L
 -4.6%
H
76.9
82.5
|
L
 -4.9%
H
76.9
84.4
|
L
 -12.3%
H
76.9
97
|
L
 41.7%
H
52.7
99.5
|
L
 99.9%
H
36.5
99.5
|
L
 160.3%
H
22.3
99.5
|
L
 78.5%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
104.7
|
3.2
|
L
 0.6%
H
3.1
3.3
|
L
 -0.6%
H
3.1
3.3
|
L
 -32.9%
H
3.1
5.5
|
L
 -2.8%
H
3.1
5.5
|
L
 33.6%
H
2.1
5.5
|
L
 -25.2%
H
2.1
6.5
|
L
 -2.8%
H
2.1
8.1
|
L
 4.6%
H
0.6
8.1
|
| Annexon Inc |
|
778.1
|
5.2
|
L
 11.3%
H
4.5
5.2
|
L
 2.2%
H
4.5
5.2
|
L
 16.3%
H
4.5
5.5
|
L
 63.6%
H
2.5
5.5
|
L
 -6.8%
H
1.3
5.5
|
L
 6.7%
H
1.3
8.4
|
L
 -78.2%
H
1.3
38.0
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
29.3
|
1.1
|
L
 -3.6%
H
1
1.1
|
L
 -6.1%
H
1
1.1
|
L
 0.9%
H
1
1.2
|
L
 -17.7%
H
1
1.4
|
L
 -24.7%
H
1
1.6
|
L
 -89.6%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
5.9
|
1.4
|
L
 -8.1%
H
1.3
1.6
|
L
 -41.6%
H
1.2
2.3
|
L
 -56.1%
H
1.2
3.4
|
L
 -68.2%
H
1.2
6.2
|
L
 -99.2%
H
0.7
186.3
|
L
 -100.0%
H
0.7
28875
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2244000
|
| Apollomics Inc (Class A) |
|
40.7
|
19.0
|
L
 -1.6%
H
17.5
19.8
|
L
 -5.1%
H
17.5
24.2
|
L
 28.8%
H
14.8
24.2
|
L
 3.0%
H
10.0
42.1
|
L
 77.6%
H
3.7
42.1
|
L
 -98.2%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
3,146.7
|
24.9
|
L
 -3.8%
H
24.5
25.9
|
L
 -0.4%
H
24.5
26.2
|
L
 12.1%
H
22.0
26.2
|
L
 4.5%
H
18.8
30.5
|
L
 -25.7%
H
16.1
35.6
|
L
 -50.3%
H
16.1
94.8
|
L
 -54.4%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
14.4
|
0.1
|
L
H
0.1
0.1
|
L
 -9.1%
H
0.1
0.1
|
L
 -56.5%
H
0.1
0.3
|
L
 -90%
H
0.1
1.5
|
L
 -88.9%
H
0.1
1.5
|
L
 -88.5%
H
0.1
10.6
|
L
 -99.5%
H
0.1
29.8
|
L
H
0.1
57.4
|
| Aptorum Grp Ltd (Class A) |
|
8.3
|
1.0
|
L
 -4.7%
H
1.0
1.1
|
L
 -10.5%
H
1.0
1.2
|
L
 -27.1%
H
1.0
1.4
|
L
 -54.7%
H
1.0
2.6
|
L
 -52.3%
H
0.7
4.5
|
L
 -81.5%
H
0.5
17.5
|
L
 -95.9%
H
0.5
49.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
6.2
|
0.9
|
L
 3.5%
H
0.8
0.9
|
L
 -10.2%
H
0.8
1.0
|
L
 -17.0%
H
0.8
1.1
|
L
 -41.3%
H
0.8
1.7
|
L
 -77.3%
H
0.8
4.7
|
L
 -88.8%
H
0.8
12
|
L
 -99.1%
H
0.8
169.2
|
L
H
0.8
1062.2
|
| Aptevo Therapeutics Inc |
|
7.8
|
8.3
|
L
 -11.4%
H
8.0
9.3
|
L
 -23.9%
H
8.0
10.7
|
L
 -66.8%
H
8.0
25.0
|
L
 -67.7%
H
8.0
35.6
|
L
 -99.5%
H
8.0
1976.4
|
L
 -100.0%
H
8.0
1512086.4
|
L
 -100.0%
H
8.0
25324516.8
|
L
H
8.0
68020444.8
|
| AquaBounty Tech Inc |
|
3.5
|
0.9
|
L
 -5.3%
H
0.9
1.0
|
L
 -11.8%
H
0.9
1.0
|
L
 -11.8%
H
0.8
1.1
|
L
 -60.5%
H
0.8
2.2
|
L
 20%
H
0.5
3.0
|
L
 -94.5%
H
0.5
23.6
|
L
 -99.5%
H
0.5
266.4
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
760.1
|
6.2
|
L
 -3.4%
H
6.2
6.5
|
L
 4.0%
H
5.9
6.6
|
L
 -3.3%
H
5.6
6.7
|
L
 7.4%
H
5.2
7.6
|
L
 74.0%
H
2.1
7.6
|
L
 600%
H
0.7
7.6
|
L
 12.5%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
181.0
|
6.4
|
L
 1.9%
H
6.1
6.4
|
L
 3.4%
H
6.0
6.4
|
L
 -6.7%
H
6.0
7.8
|
L
 -71.8%
H
5.9
24.2
|
L
 -64.5%
H
5.9
24.2
|
L
 -62.6%
H
5.9
45
|
L
 -87.0%
H
5.9
89.2
|
L
 -85.4%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,479.7
|
6.1
|
L
 -1.0%
H
5.7
6.2
|
L
 6.1%
H
5.7
6.4
|
L
 2.9%
H
5.6
6.4
|
L
 15.8%
H
4.7
6.7
|
L
 19.4%
H
3.2
6.8
|
L
 116.7%
H
2.7
10.1
|
L
 -5.9%
H
0.5
10.1
|
L
 -64.6%
H
0.5
17.9
|
| Arcutis Biotherapeutics Inc |
|
3,699.3
|
30.2
|
L
 4.1%
H
28.6
30.2
|
L
 4.3%
H
27.7
30.2
|
L
 -3.1%
H
27.5
31.8
|
L
 51.6%
H
19.4
31.8
|
L
 106.6%
H
11.1
31.8
|
L
 92.5%
H
1.8
31.8
|
L
 6.2%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.6
|
1.3
|
L
 2.4%
H
1.3
1.3
|
L
 -12.8%
H
1.2
1.5
|
L
 -36.9%
H
1.2
2.1
|
L
 -72.3%
H
1.2
5.0
|
L
 -80.1%
H
1.2
28.6
|
L
 -92.7%
H
1.2
28.6
|
L
 -98.3%
H
1.2
330.3
|
L
H
1.2
15552
|
| Arvinas Inc |
|
717.4
|
11.2
|
L
 -2.6%
H
11
11.6
|
L
 -8.1%
H
11
12.1
|
L
 -11%
H
11
13.6
|
L
 16.2%
H
8.8
14.2
|
L
 -45.5%
H
5.9
20.9
|
L
 -68.8%
H
5.9
53.1
|
L
 -86.7%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
8,675.5
|
63.9
|
L
 -5.8%
H
60.6
68.3
|
L
 -9.0%
H
60.6
69.7
|
L
 -1.2%
H
59.5
72.4
|
L
 76.9%
H
34.6
72.4
|
L
 222.8%
H
9.6
72.4
|
L
 67.8%
H
9.6
72.4
|
L
 -14.6%
H
9.6
93.7
|
L
 968.2%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
511.1
|
32.3
|
L
 -4.2%
H
32.2
33.7
|
L
 -3.9%
H
31.7
34.7
|
L
 -8.4%
H
31.5
39.0
|
L
 38.6%
H
23.2
39.7
|
L
 84.7%
H
7.8
39.7
|
L
 96.5%
H
7.7
39.7
|
L
 -55.4%
H
7.7
84.2
|
L
 -62.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
724.9
|
6.5
|
L
 16.2%
H
6.0
6.6
|
L
 13.5%
H
5.2
6.6
|
L
 -2.0%
H
5.2
6.8
|
L
 -30.0%
H
5.2
14.5
|
L
 29.8%
H
3.7
14.5
|
L
 291.6%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
61.8
|
9.6
|
L
 5.4%
H
9.2
9.9
|
L
 -3.1%
H
8.6
10.1
|
L
 -18.1%
H
8.6
12
|
L
 -29.5%
H
8.6
14.3
|
L
 -27.5%
H
7.7
15.2
|
L
 -84.9%
H
7.7
120.2
|
L
 -63.5%
H
7.7
120.2
|
L
 -99.1%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,405.6
|
3.9
|
L
H
3.6
3.9
|
L
 -4.9%
H
3.6
4.2
|
L
 -12.1%
H
3.6
4.7
|
L
 -26%
H
3.6
6.8
|
L
 118.6%
H
1.2
6.8
|
L
 43.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| Athira Pharma Inc |
|
26.0
|
6.6
|
L
 -5.5%
H
6.4
7.2
|
L
 -12.0%
H
6.4
7.8
|
L
 68.7%
H
3.8
8.4
|
L
 58.9%
H
3.6
8.4
|
L
 14.4%
H
2.2
8.4
|
L
 -81.6%
H
2.2
44.1
|
L
 -97.8%
H
2.2
304.9
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
101.9
|
5.4
|
L
 4.9%
H
5.2
5.5
|
L
 3.5%
H
4.9
5.5
|
L
 -54.5%
H
4.9
11.7
|
L
 -78.8%
H
4.9
27.1
|
L
 -68.5%
H
4.9
174.6
|
L
 -99.4%
H
4.9
1358.5
|
L
 -99.9%
H
4.9
49571
|
L
H
4.9
49571
|
| Atossa Therapeutics Inc |
|
80.1
|
0.6
|
L
 -1.6%
H
0.6
0.7
|
L
 -6.1%
H
0.6
0.7
|
L
 -18.4%
H
0.6
1.0
|
L
 -38.6%
H
0.6
1.3
|
L
 -39.2%
H
0.6
1.3
|
L
H
0.6
2.3
|
L
 -34.7%
H
0.5
9.8
|
L
 -99.0%
H
0.5
127.8
|
| Atara Biotherapeutics Inc |
|
121.6
|
16.9
|
L
 -5.1%
H
16.6
19.1
|
L
 -2.4%
H
16.6
19.1
|
L
 18.7%
H
14.1
19.1
|
L
 17%
H
10.5
19.1
|
L
 3.1%
H
5
19.1
|
L
 -79.9%
H
0.4
141
|
L
 -96.6%
H
0.4
546.3
|
L
 -97.2%
H
0.4
1361.3
|
| Astria Therapeutics Inc |
|
731.8
|
12.8
|
L
 -0.5%
H
12.7
12.9
|
L
 -1%
H
12.7
13.1
|
L
 -2.3%
H
12.6
13.2
|
L
 70.5%
H
7.4
13.3
|
L
 44.4%
H
3.6
13.3
|
L
 -14.6%
H
3.6
16.9
|
L
 -5.0%
H
2.4
47.8
|
L
 -97.1%
H
2.4
489
|
| Aurinia Pharma Inc |
|
2,017.2
|
15.3
|
L
 -0.3%
H
14.8
15.4
|
L
 -5.9%
H
14.8
16.2
|
L
 -0.1%
H
14.8
16.5
|
L
 34.8%
H
10.9
16.5
|
L
 75.1%
H
6.6
16.5
|
L
 127.7%
H
4.7
16.5
|
L
 13.0%
H
4.1
34.0
|
L
 537.5%
H
1.4
34.0
|
| Aura Biosciences Inc |
|
328.9
|
5.2
|
L
 -2.3%
H
5.0
5.4
|
L
 -11.8%
H
5.0
6.3
|
L
 -19.7%
H
5.0
6.7
|
L
 -14.4%
H
5.0
6.7
|
L
 -38.0%
H
4.3
8.6
|
L
 -51.5%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
266.4
|
3.4
|
L
 -2.0%
H
3.3
3.5
|
L
 -6.6%
H
3.3
3.6
|
L
 10.4%
H
3.1
3.7
|
L
 17.6%
H
2.8
3.7
|
L
 -4.8%
H
2.5
4.0
|
L
 -28.7%
H
2.5
5.2
|
L
 -91.8%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
368.9
|
19.7
|
L
 -5.7%
H
19.0
21.2
|
L
 -5.6%
H
19.0
22
|
L
 -6.1%
H
17.8
22
|
L
 29.3%
H
14.6
26
|
L
 -59.4%
H
13.7
61.1
|
L
 94.4%
H
1.4
61.1
|
L
 -88.7%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
647.0
|
13.1
|
L
 -7.3%
H
12.5
14.1
|
L
 -20.2%
H
12.5
16.8
|
L
 5.8%
H
12.1
17.7
|
L
 48.1%
H
8.4
17.7
|
L
 -86.0%
H
6.6
100.1
|
L
 -98.6%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
290.7
|
16.0
|
L
 -5.8%
H
15.2
17.2
|
L
 -12.7%
H
15.2
18.6
|
L
 -10.7%
H
15.2
20.7
|
L
 19.6%
H
13.2
20.7
|
L
 91.1%
H
3.4
20.7
|
L
 211.9%
H
0.0
34.5
|
L
 -49.4%
H
0.0
54
|
L
 -65.3%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
352.9
|
4.0
|
L
 7.3%
H
3.6
4.0
|
L
 8.5%
H
3.5
4.0
|
L
 -11.2%
H
3.5
4.9
|
L
 -60.3%
H
2.9
10.4
|
L
 -68.0%
H
2.9
14.3
|
L
 -60.4%
H
2.9
14.4
|
L
 -25.3%
H
2.9
31.5
|
L
 -36.9%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,645.3
|
171.5
|
L
 -4.0%
H
168.6
179.0
|
L
 12.8%
H
148.1
184.4
|
L
 15.8%
H
144
184.4
|
L
 42.6%
H
117.3
184.4
|
L
 98.4%
H
79.2
184.4
|
L
 133.8%
H
53.7
184.4
|
L
 110.6%
H
19.4
184.4
|
L
 1306.8%
H
1.9
184.4
|
| Aytu BioPharma Inc |
|
29.5
|
2.9
|
L
 4.7%
H
2.9
3.1
|
L
 18.4%
H
2.4
3.1
|
L
 29.5%
H
2.2
3.1
|
L
 52.6%
H
1.8
3.1
|
L
 62.9%
H
1.0
3.1
|
L
 -27.7%
H
1.0
4.4
|
L
 -97.7%
H
1.0
235.3
|
L
 -100.0%
H
1.0
2640000
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.6
|
L
 -4.7%
H
0.6
0.7
|
L
 13.0%
H
0.5
0.7
|
L
 -11.6%
H
0.5
0.7
|
L
 -30.7%
H
0.5
1
|
L
 -64.5%
H
0.5
2.6
|
L
 -85.0%
H
0.5
5.4
|
L
 -95.4%
H
0.5
18.2
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
83.9
|
1.8
|
L
 -3.3%
H
1.8
1.8
|
L
H
1.7
1.9
|
L
 -9.6%
H
1.6
2.1
|
L
 -10.1%
H
1.3
2.1
|
L
 -11.9%
H
1.3
3.2
|
L
 29.9%
H
1.1
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
10.0
|
8.1
|
L
H
7.7
8.1
|
L
 1.3%
H
7.7
8.2
|
L
 -3.5%
H
7.0
8.9
|
L
 -12.1%
H
7.0
12.0
|
L
 -3.4%
H
6.5
12.1
|
L
 -43.8%
H
5
45.6
|
L
 -97.1%
H
5
377.4
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
10.4
|
0.3
|
L
H
0.3
0.3
|
L
 7.4%
H
0.3
0.3
|
L
 -14.7%
H
0.2
0.5
|
L
 -68.5%
H
0.2
1.1
|
L
 -77.9%
H
0.2
1.7
|
L
 -97.2%
H
0.2
11
|
L
 -99.2%
H
0.2
84.2
|
L
 -99.9%
H
0.2
444
|
| Amarin Corp (ADR) |
|
280.7
|
13.5
|
L
 -1.6%
H
13.1
13.8
|
L
 -4.5%
H
13.1
14.5
|
L
 -18.0%
H
13.1
16.7
|
L
 -28.3%
H
13.1
20.9
|
L
 2447.2%
H
0.4
20.9
|
L
 988.7%
H
0.4
20.9
|
L
 168.4%
H
0.4
20.9
|
L
 645.9%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
49,309.3
|
800.9
|
L
 -4.7%
H
787.0
835.5
|
L
 -5.2%
H
787.0
855.4
|
L
 -12.6%
H
787.0
917.7
|
L
 0.1%
H
749.8
934.6
|
L
 28.9%
H
510.1
934.6
|
L
 112.7%
H
327.7
934.6
|
L
 169.6%
H
248.2
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
13,023.1
|
213.2
|
L
 -0.1%
H
205.0
213.7
|
L
 2%
H
205.0
216.0
|
L
 2.2%
H
192.3
229.9
|
L
 4.5%
H
186.1
229.9
|
L
 51.8%
H
118.0
229.9
|
L
 74.6%
H
64.3
229.9
|
L
 28.8%
H
61.6
229.9
|
L
 1082.2%
H
11.9
229.9
|
| Alterity Therapeutics Ltd (ADR) |
|
58.9
|
3.3
|
L
 2.9%
H
3.2
3.3
|
L
 2.5%
H
3.0
3.3
|
L
 -5.3%
H
2.7
3.5
|
L
 -23.5%
H
2.7
5.2
|
L
 -17.1%
H
2.5
7
|
L
 -10.2%
H
1
7
|
L
 -76.8%
H
1
27.5
|
L
 -92.4%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
495.0
|
1.9
|
L
 -0.5%
H
1.8
1.9
|
L
 11.4%
H
1.7
2.0
|
L
 18.5%
H
1.5
2.0
|
L
 15.5%
H
1.2
2.0
|
L
 -30.6%
H
1.1
2.7
|
L
H
1.1
7.5
|
L
 -80.1%
H
1.1
10.0
|
L
H
1.1
53.2
|
| Avadel Pharma PLC (ADR) |
|
2,110.0
|
21.5
|
L
 -0.1%
H
21.5
21.5
|
L
 -0.4%
H
21.5
21.6
|
L
 0.7%
H
21.3
21.7
|
L
 43.2%
H
13.8
23.6
|
L
 94.4%
H
6.4
23.6
|
L
 200.7%
H
6.4
23.6
|
L
 222.8%
H
1.1
23.6
|
L
 66.4%
H
1.0
23.6
|
| Astrazeneca PLC (ADR) |
|
282,833.7
|
91.2
|
L
 -0.4%
H
89.5
91.4
|
L
 -1.8%
H
89.5
92.9
|
L
 1.3%
H
89.3
93.1
|
L
 6.9%
H
80.5
94.0
|
L
 37.7%
H
61.2
94.0
|
L
 31.3%
H
60.5
94.0
|
L
 80.6%
H
46.5
94.0
|
L
 173.1%
H
25.6
94.0
|
| BridgeBio Pharma Inc |
|
14,148.7
|
73.4
|
L
 -6.2%
H
72.0
78.6
|
L
 -3.1%
H
72.0
78.6
|
L
 -1.8%
H
70.4
78.6
|
L
 38.9%
H
52.8
78.6
|
L
 161.1%
H
27.9
78.6
|
L
 831.7%
H
7.1
78.6
|
L
 15.4%
H
5.0
78.6
|
L
H
5.0
78.6
|
| BioAtla Inc |
|
24.7
|
0.4
|
L
 -20.8%
H
0.4
0.6
|
L
 -50%
H
0.4
0.8
|
L
 -50.6%
H
0.4
0.9
|
L
 -39.1%
H
0.4
1.4
|
L
 -31.2%
H
0.2
1.4
|
L
 -94.8%
H
0.2
8.7
|
L
 -98.8%
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
13.5
|
1.3
|
L
H
1.3
1.3
|
L
H
1.2
1.3
|
L
 -13.6%
H
1.2
1.5
|
L
 -6.6%
H
1.2
1.6
|
L
 -45.0%
H
1
3.2
|
L
 -96.1%
H
1
43.8
|
L
 -97.6%
H
1
82.2
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
1,561.6
|
7.4
|
L
 -1.2%
H
7.2
7.5
|
L
 -2.9%
H
7.2
7.9
|
L
 -5.4%
H
7.1
8.0
|
L
 3.6%
H
6
8.2
|
L
 -3.8%
H
6
11.3
|
L
 -37.4%
H
4.0
12.1
|
L
 0.4%
H
4.0
20.0
|
L
 -24.4%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
14.4
|
7.7
|
L
 6.7%
H
7.2
8.2
|
L
 -1.2%
H
6.9
8.2
|
L
 -37.5%
H
6.6
13.1
|
L
 -41.5%
H
6.6
14.7
|
L
 -99.2%
H
6.6
982
|
L
 -99.9%
H
6.6
12033
|
L
 -99.9%
H
6.6
18526.5
|
L
 -100.0%
H
6.6
138373.2
|
| Black Diamond Therapeutics Inc |
|
146.4
|
2.6
|
L
 3.2%
H
2.5
2.6
|
L
 -0.8%
H
2.4
2.6
|
L
 -5.2%
H
2.4
2.9
|
L
 -33.9%
H
2.2
4.9
|
L
 16.8%
H
1.2
4.9
|
L
 28.5%
H
1.2
7.7
|
L
 -92.0%
H
1.2
37.8
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,723.6
|
26.8
|
L
 -1.1%
H
26.3
28.0
|
L
 -4.1%
H
26.3
28.7
|
L
 -7.2%
H
25.5
28.9
|
L
 4.2%
H
20.2
31.5
|
L
 5.8%
H
13.5
35.3
|
L
 -34.9%
H
13.5
50.7
|
L
 -67.7%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
9.3
|
0.8
|
L
 11.1%
H
0.7
0.9
|
L
 11.1%
H
0.6
0.9
|
L
 -3.6%
H
0.6
0.9
|
L
 -25.2%
H
0.6
1.2
|
L
 -25.9%
H
0.5
1.9
|
L
 -95.5%
H
0.5
22.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
25,618.6
|
174.6
|
L
 -1.8%
H
171.6
180.6
|
L
 -1.4%
H
171.6
180.6
|
L
 -4.0%
H
168.6
183.1
|
L
 9.2%
H
138
185.2
|
L
 15.1%
H
110.0
185.2
|
L
 -35.5%
H
110.0
319.8
|
L
 -28.1%
H
110.0
468.6
|
L
 -35.7%
H
110.0
468.6
|
| BioVie Inc |
|
9.9
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 8.3%
H
1.1
1.4
|
L
 -18.6%
H
1.1
1.6
|
L
 -32.8%
H
1.1
2.1
|
L
 -94.1%
H
1.1
25.8
|
L
 -99.8%
H
1.1
1139
|
L
 -99.9%
H
1.1
4609.8
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
90.5
|
1.3
|
L
 -4.5%
H
1.3
1.4
|
L
 -3.0%
H
1.2
1.4
|
L
 7.6%
H
1.2
1.6
|
L
 -40.5%
H
0.9
3.0
|
L
 -65.7%
H
0.9
4.6
|
L
 -83.3%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,309.8
|
58.9
|
L
 -1.0%
H
58.4
59.6
|
L
 -1.8%
H
58.4
60.6
|
L
 9.4%
H
50.9
63.9
|
L
 6.2%
H
50.8
63.9
|
L
 -11.9%
H
50.8
73.5
|
L
 -44.9%
H
50.8
117.8
|
L
 -31.8%
H
50.8
117.8
|
L
 -43.9%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
16.2
|
1.6
|
L
H
1.6
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 -6.5%
H
1.5
1.7
|
L
 -17.2%
H
1.5
2.2
|
L
 396.9%
H
0.1
11.6
|
L
 -89.3%
H
0.1
20.2
|
L
 -97.8%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
402.6
|
11.9
|
L
 -5.5%
H
11.5
12.8
|
L
 -9.2%
H
11.5
14.4
|
L
 -9.8%
H
9.9
14.4
|
L
 -14.1%
H
9.9
16.8
|
L
 -1.7%
H
9.7
17.2
|
L
 275.1%
H
1.9
17.2
|
L
 -79.1%
H
1.9
178.3
|
L
 -98.9%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
10.9
|
5.7
|
L
 -2.3%
H
5.7
5.9
|
L
 6.2%
H
5.1
5.9
|
L
 6.6%
H
5
6.2
|
L
 6.6%
H
4.4
6.6
|
L
 -50.4%
H
4.4
12.6
|
L
 -79.9%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Bon Natural Life Ltd |
|
13.8
|
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 5.6%
H
1.5
1.7
|
L
 -5.6%
H
1.5
1.9
|
L
 -15%
H
1.5
2.3
|
L
 -96.1%
H
1.1
73.8
|
L
 -99.4%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
39.1
|
1.8
|
L
 5.3%
H
1.7
1.8
|
L
 7.8%
H
1.5
1.8
|
L
 -14.4%
H
1.5
2.3
|
L
 -29.3%
H
1.5
2.9
|
L
 336.6%
H
0.2
8.1
|
L
 -92.0%
H
0.2
34.1
|
L
 -96.6%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
29.6
|
1.7
|
L
 3.1%
H
1.5
1.7
|
L
 16.1%
H
1.4
1.7
|
L
 -43.7%
H
1.4
3.2
|
L
 -46.8%
H
1.4
4.2
|
L
 1975%
H
0.1
5.9
|
L
 44.3%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
62.1
|
1.5
|
L
 -6.2%
H
1.5
1.7
|
L
 -17.9%
H
1.5
1.8
|
L
 -21.8%
H
1.5
2.4
|
L
 -13.7%
H
1.5
2.4
|
L
 -7.4%
H
1.0
3.4
|
L
 -17.9%
H
0.7
4
|
L
 -87.6%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
458.5
|
6.6
|
L
 -1.1%
H
6.3
6.9
|
L
 -3.1%
H
6.3
7.2
|
L
 -7.4%
H
6.3
7.7
|
L
 -21.0%
H
6.0
9.2
|
L
 -54.9%
H
6.0
15.4
|
L
 -78.5%
H
6.0
31.9
|
L
 -65.6%
H
6.0
62.1
|
L
H
6.0
62.1
|
| Biodexa Pharma PLC (ADR) |
|
2.1
|
2.5
|
L
 2.0%
H
2.4
2.6
|
L
 -4.6%
H
2.2
2.6
|
L
 -50.7%
H
2.2
8.9
|
L
 -62.5%
H
2.2
11.9
|
L
 -94.4%
H
2.2
92
|
L
 -100.0%
H
2.2
1920000
|
L
 -100.0%
H
2.2
38295000
|
L
 -100.0%
H
2.2
2860012306.1
|
| BeiGene Ltd (ADR) |
|
34,120.3
|
320.3
|
L
 3.0%
H
312.7
328.0
|
L
 2.5%
H
302.1
328.0
|
L
 -3.4%
H
299.5
332.6
|
L
 -6.9%
H
299.5
385.2
|
L
 40.3%
H
228.9
385.2
|
L
 31.9%
H
127.0
385.2
|
L
 22.7%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
12.5
|
2.9
|
L
 2.9%
H
2.8
3.0
|
L
 -0.7%
H
2.7
3.1
|
L
 -11.7%
H
2.7
3.4
|
L
 -28%
H
2.7
4.6
|
L
 -73.7%
H
0.1
7.8
|
L
 -89.6%
H
0.1
101.2
|
L
 -97.1%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,980.6
|
159.4
|
L
 0.1%
H
153.6
160.5
|
L
 2.9%
H
151.5
169.8
|
L
 5.4%
H
140.1
169.8
|
L
 110.9%
H
76.0
169.8
|
L
 156.8%
H
49
169.8
|
L
 434.8%
H
11
169.8
|
L
H
6
169.8
|
L
H
6
169.8
|
| Neuphoria Therapeutics Inc |
|
20.6
|
3.8
|
L
 0.5%
H
3.8
4.0
|
L
 3.2%
H
3.6
4.0
|
L
 -10.1%
H
3.6
4.7
|
L
 -80.3%
H
3.6
21.4
|
L
 27.6%
H
3
21.4
|
L
 -7.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
24,302.6
|
96.9
|
L
 0.2%
H
95.9
98.1
|
L
 2.5%
H
94
98.1
|
L
 0.9%
H
91.1
99.6
|
L
 -8.2%
H
91.1
113.4
|
L
 -16.4%
H
81.2
129.3
|
L
 -33.7%
H
76.5
156.3
|
L
 13.0%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 7.1%
H
0.6
0.8
|
L
 -29.9%
H
0.6
1.3
|
L
 -43.6%
H
0.6
1.6
|
L
 -74.2%
H
0.6
6.2
|
L
 -74.8%
H
0.6
6.2
|
L
 -97.7%
H
0.6
99
|
L
 -98.0%
H
0.6
620
|
| Cabaletta Bio Inc |
|
211.8
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 0.5%
H
2.1
2.3
|
L
 -14.1%
H
2.1
2.7
|
L
 -9.8%
H
2.0
3.7
|
L
 -8.3%
H
1.0
3.7
|
L
 -79.2%
H
1.0
26.4
|
L
 -82.9%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
86.6
|
6.0
|
L
 -10.8%
H
5.9
7.0
|
L
 -3.5%
H
5.6
7.2
|
L
 31.5%
H
4.1
7.2
|
L
 87.8%
H
3.0
7.2
|
L
 86.7%
H
1.4
7.2
|
L
 -34.0%
H
1
10.6
|
L
 -98.5%
H
1
492.5
|
L
H
1
530.3
|
| Capricor Therapeutics Inc |
|
1,349.6
|
24.8
|
L
 -12.4%
H
24.3
28.5
|
L
 -16.4%
H
24.3
30.7
|
L
 -2.3%
H
24.3
31.4
|
L
 237.1%
H
4.3
40.4
|
L
 58.9%
H
4.3
40.4
|
L
 528.1%
H
2.7
40.4
|
L
 563.4%
H
2.6
40.4
|
L
 -15.6%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
37.8
|
4.0
|
L
 -1.2%
H
4.0
4.2
|
L
 -2.7%
H
4.0
4.5
|
L
 -3.6%
H
3.8
4.7
|
L
 -90.0%
H
3.7
43.7
|
L
 -74.3%
H
3.7
43.7
|
L
 -99.0%
H
3.7
449.6
|
L
 -99.3%
H
3.7
1067.3
|
L
 -99.3%
H
3.7
1067.3
|
| CASI Pharma Inc |
|
17.5
|
0.9
|
L
 3.7%
H
0.8
0.9
|
L
 7.6%
H
0.8
0.9
|
L
 -13.3%
H
0.8
1.1
|
L
 -54.1%
H
0.8
2.1
|
L
 -70.7%
H
0.8
3.1
|
L
 -56.0%
H
0.8
8.5
|
L
 -97.0%
H
0.8
39
|
L
 -91.1%
H
0.8
88.9
|
| Crescent Biopharma Inc |
|
-
|
11.1
|
L
 0.3%
H
10.9
11.6
|
L
 -10.0%
H
10.9
12.6
|
L
 -14.5%
H
10.9
15.6
|
L
 -5.2%
H
9.8
16.4
|
L
 -2.1%
H
7.6
21.4
|
L
 99.5%
H
2.8
21.4
|
L
 -26.1%
H
0.9
21.4
|
L
 -90.1%
H
0.9
124.5
|
| C4 Therapeutics Inc |
|
196.7
|
2.0
|
L
 5.2%
H
2.0
2.2
|
L
 -4.3%
H
1.9
2.2
|
L
 -21.6%
H
1.9
2.8
|
L
 -10.6%
H
1.9
2.8
|
L
 -48.2%
H
1.1
4.3
|
L
 -69.4%
H
1.1
11.9
|
L
 -93.6%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Cidara Therapeutics Inc |
|
6,959.7
|
221.3
|
L
 0.1%
H
221.1
221.4
|
L
 0.2%
H
220.4
221.4
|
L
 0.4%
H
219.6
221.4
|
L
 117%
H
93
221.4
|
L
 731.4%
H
15.2
221.4
|
L
 -32.0%
H
10
840
|
L
 -73.1%
H
10
1260
|
L
 -96.7%
H
10
6900
|
| Niagen Bioscience Inc |
|
514.7
|
6.5
|
L
 3.2%
H
6.3
6.5
|
L
 -2.9%
H
6.2
6.8
|
L
 -3.7%
H
6.2
7.1
|
L
 -6.9%
H
6.2
8.0
|
L
 15.6%
H
5.2
14.7
|
L
 268.6%
H
1.3
14.7
|
L
 35.8%
H
1.2
23.7
|
L
 76.2%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
590.2
|
10.0
|
L
 -1.3%
H
9.4
10.2
|
L
 -3.7%
H
9.4
10.7
|
L
 -5.6%
H
9.4
13.1
|
L
 69.3%
H
5.7
13.3
|
L
 -21.2%
H
5.7
13.3
|
L
 -7.2%
H
5.7
30.2
|
L
H
5.7
59.9
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
142.2
|
1.5
|
L
 -1.9%
H
1.5
1.6
|
L
 -1.3%
H
1.4
1.6
|
L
 -5.6%
H
1.4
1.7
|
L
 -6.8%
H
1.4
2.4
|
L
 -5%
H
1.1
2.7
|
L
 100%
H
0.5
3.0
|
L
 -88.1%
H
0.5
14.3
|
L
 -76.4%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
123.6
|
1.4
|
L
 -4.8%
H
1.4
1.5
|
L
 -3.5%
H
1.3
1.5
|
L
 -20.5%
H
1.3
1.8
|
L
 -9.7%
H
1.3
2.1
|
L
 97.2%
H
0.2
3.8
|
L
 -38.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
174.1
|
1.4
|
L
 5.1%
H
1.4
1.5
|
L
 8.3%
H
1.3
1.5
|
L
 17.1%
H
1.2
1.5
|
L
 -12.2%
H
1.1
1.9
|
L
 -6.5%
H
0.7
1.9
|
L
 -85.4%
H
0.7
11.0
|
L
 -91.5%
H
0.7
22.2
|
L
 -93.2%
H
0.7
32.0
|
| Cingulate Inc |
|
34.1
|
4.8
|
L
 8.5%
H
4.3
4.8
|
L
 13.6%
H
3.9
4.8
|
L
 20.6%
H
3.8
4.8
|
L
 13.6%
H
3.2
4.8
|
L
 -5.9%
H
3.2
6.0
|
L
 365.7%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
59.5
|
5.8
|
L
 -0.2%
H
5.7
6.2
|
L
 -7.8%
H
5.5
6.3
|
L
 -8.4%
H
5.4
7.0
|
L
 -45.2%
H
5.4
13.5
|
L
 5.1%
H
2.3
13.5
|
L
 -70.1%
H
2.3
39.8
|
L
 -96.2%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
14.2
|
3.4
|
L
 -3.5%
H
3.3
3.7
|
L
 30.9%
H
2.5
3.7
|
L
 -11.8%
H
2.5
4.1
|
L
 -42.0%
H
2.5
6.5
|
L
 -67.6%
H
2.5
20.6
|
L
 -93.1%
H
2.5
133.5
|
L
 -99.5%
H
2.5
894
|
L
 -100.0%
H
2.5
36924.2
|
| Clearmind Medicine Inc |
|
3.7
|
2.5
|
L
 25.1%
H
2.1
2.6
|
L
 12.7%
H
1.7
2.6
|
L
 -52.8%
H
1.7
5.3
|
L
 -93.8%
H
1.7
48
|
L
 -95.8%
H
1.7
70
|
L
 -99.9%
H
1.7
6120
|
L
 -100.0%
H
1.7
788400
|
L
H
1.7
788400
|
| Compass Therapeutics Inc |
|
887.5
|
5.0
|
L
 -3.5%
H
4.9
5.4
|
L
 -3.5%
H
4.9
5.5
|
L
 -9.9%
H
4.8
5.8
|
L
 34.9%
H
3.4
5.9
|
L
 219.9%
H
1.3
5.9
|
L
 -1.6%
H
0.8
5.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
3.3
|
5.3
|
L
 -0.4%
H
5.3
5.4
|
L
 -14.4%
H
5.2
6.2
|
L
 -18.9%
H
5.2
8.1
|
L
 -41.1%
H
5.2
10.6
|
L
 -99.9%
H
4.9
5700
|
L
 -100.0%
H
4.9
6600000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
142.4
|
1.6
|
L
H
1.5
2
|
L
 37.2%
H
1.1
2
|
L
 50.5%
H
1
2
|
L
 40.9%
H
1
2
|
L
 24%
H
0.5
2
|
L
 109.5%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
15.0
|
1.1
|
L
 10.1%
H
1.0
1.1
|
L
 12.4%
H
0.9
1.1
|
L
 4.8%
H
0.9
1.1
|
L
 -9.9%
H
0.9
1.3
|
L
 -53.6%
H
0.9
2.7
|
L
 -47.3%
H
0.9
3.3
|
L
 -93.6%
H
0.9
41.5
|
L
 -99.6%
H
0.9
309.6
|
| Co-Diagnostics Inc |
|
12.0
|
5.7
|
L
 3.2%
H
5.3
5.8
|
L
 -18.6%
H
4.8
7.2
|
L
 -50.6%
H
4.8
12
|
L
 -50.2%
H
4.8
46.5
|
L
 -75.5%
H
4.8
46.5
|
L
 -92.7%
H
4.8
99.9
|
L
 -98.1%
H
4.8
620.6
|
L
H
4.8
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
79.0
|
14.8
|
L
 1.0%
H
14.3
14.9
|
L
 1.0%
H
13.9
15.1
|
L
 -9.9%
H
13.6
16.6
|
L
 -13%
H
13
21.4
|
L
 158.6%
H
3.8
21.4
|
L
 -59.8%
H
2.3
43.8
|
L
 47.0%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,259.1
|
34.3
|
L
 -1.4%
H
32.9
34.7
|
L
 -11.9%
H
32.9
38.8
|
L
 -12.9%
H
32.9
43.7
|
L
 117.4%
H
13.8
43.7
|
L
 333.1%
H
3.7
43.7
|
L
 197.9%
H
3.7
43.7
|
L
 178.5%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,444.0
|
45.7
|
L
 0.3%
H
44.5
45.8
|
L
 -8.4%
H
44.5
50.8
|
L
 -3.7%
H
44.5
50.8
|
L
 32.0%
H
31.3
50.8
|
L
 54.8%
H
23.2
50.8
|
L
 69.3%
H
20.8
50.8
|
L
 130.0%
H
14.0
50.8
|
L
 74.2%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
3,676.3
|
35.0
|
L
 -8.5%
H
34.9
38.2
|
L
 -57.7%
H
33.0
83.0
|
L
 -58.7%
H
33.0
89
|
L
 -60.4%
H
33.0
91
|
L
 -31.3%
H
33.0
117.3
|
L
 72.7%
H
17.9
117.3
|
L
 34.0%
H
15.8
117.3
|
L
 650%
H
3.2
117.3
|
| Cosmos Health Inc |
|
19.8
|
0.5
|
L
 1.9%
H
0.5
0.6
|
L
 3.9%
H
0.5
0.6
|
L
 6%
H
0.4
0.6
|
L
 -50.9%
H
0.4
1.3
|
L
 -24.3%
H
0.3
1.3
|
L
 -90.2%
H
0.3
7.4
|
L
 -99.6%
H
0.3
225
|
L
 -99.7%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
59.8
|
4
|
L
 0.5%
H
3.8
4.3
|
L
 -2.9%
H
3.8
4.3
|
L
 70.2%
H
2.2
4.6
|
L
 27.8%
H
1.9
4.6
|
L
 73.9%
H
1.9
7.3
|
L
 68.8%
H
1.0
7.3
|
L
 33.8%
H
1.0
7.5
|
L
 -21.1%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,802.4
|
22.8
|
L
 -1.5%
H
22.3
23.1
|
L
 -6.4%
H
22.3
24.5
|
L
 -1.2%
H
22.2
25.1
|
L
 9.4%
H
19.9
25.1
|
L
 6.2%
H
19.1
26.6
|
L
 22.9%
H
11.1
26.6
|
L
 545.9%
H
3.3
26.6
|
L
 882.8%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
137.4
|
7.8
|
L
 -0.5%
H
7.6
8.2
|
L
 -6%
H
7.6
8.4
|
L
 -26.8%
H
7.6
11.6
|
L
 -47.2%
H
7.6
20.6
|
L
 -40.0%
H
4.6
20.6
|
L
 100.8%
H
2.1
61.9
|
L
 -79.4%
H
2.1
120
|
L
 -83.8%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
150.5
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 -5.3%
H
1.5
1.7
|
L
 -17.0%
H
1.5
2.0
|
L
 -29.1%
H
1.5
3.5
|
L
 -6.4%
H
0.7
3.5
|
L
 -77.4%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
100.0
|
1
|
L
 1.0%
H
1.0
1.0
|
L
 1.0%
H
0.9
1.0
|
L
 4.2%
H
0.9
1.1
|
L
 -6.5%
H
0.9
1.4
|
L
 -30.6%
H
0.8
1.6
|
L
 69.5%
H
0.5
3.1
|
L
 -63.9%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
12.7
|
1.0
|
L
H
1.0
1.0
|
L
 -7.6%
H
1.0
1.1
|
L
 -27.4%
H
1.0
1.4
|
L
 -40.6%
H
1.0
1.7
|
L
 -76.0%
H
1.0
3.9
|
L
 -92.2%
H
1.0
20
|
L
 -99.5%
H
1.0
348
|
L
 -99.6%
H
1.0
372
|
| CorMedix Inc |
|
960.4
|
12.2
|
L
 0.3%
H
11.7
12.2
|
L
 -2.7%
H
11.6
13.0
|
L
 14.6%
H
10.4
13.0
|
L
 7.5%
H
9.2
13.0
|
L
 49.0%
H
5.6
17.4
|
L
 180.2%
H
2.6
17.4
|
L
 65.2%
H
2.6
18.8
|
L
 28.3%
H
0.9
22.7
|
| Crinetics Pharma Inc |
|
4,571.9
|
48.2
|
L
 3.1%
H
46.9
58.0
|
L
 0.5%
H
45.5
58.0
|
L
 1.6%
H
43.0
58.0
|
L
 17.9%
H
38.8
58.0
|
L
 -9.4%
H
24.1
58.0
|
L
 177.1%
H
15.2
62.5
|
L
 245.4%
H
13.3
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
1,033.8
|
2.7
|
L
H
2.6
2.7
|
L
 1.5%
H
2.6
2.7
|
L
 8.4%
H
2.4
3.4
|
L
 4.7%
H
2.3
3.4
|
L
 30.4%
H
1.6
3.4
|
L
 3.8%
H
1.6
3.4
|
L
 -64.5%
H
1.6
15.8
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,255.8
|
55.2
|
L
 2.6%
H
53.7
55.5
|
L
 0.1%
H
52.1
55.5
|
L
 -5.2%
H
52.1
59.2
|
L
 -18.6%
H
48.0
78.5
|
L
 34.5%
H
30.0
78.5
|
L
 22.6%
H
30.0
91.1
|
L
 -65.1%
H
30.0
220.2
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
507.1
|
6.8
|
L
 -7.2%
H
6.7
7.4
|
L
 -11.8%
H
6.7
7.9
|
L
 -22.9%
H
6.7
9.6
|
L
 -5.6%
H
6.4
9.6
|
L
 16.5%
H
2.5
9.6
|
L
 638.0%
H
0.6
10
|
L
 79.6%
H
0.6
10
|
L
H
0.6
22.1
|
| Champions Oncology Inc |
|
93.2
|
6.7
|
L
 0.8%
H
6.6
6.7
|
L
 -3.9%
H
6.5
7.1
|
L
 10%
H
6.0
8.3
|
L
 6.5%
H
6.0
8.3
|
L
 -22.0%
H
5.6
12.0
|
L
 52.5%
H
3.6
12.0
|
L
 -37.9%
H
3.6
14.7
|
L
 77.5%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
698.1
|
4.1
|
L
 -3.1%
H
4.0
4.3
|
L
 -6.2%
H
4.0
4.7
|
L
 1.0%
H
3.8
4.7
|
L
 24.9%
H
3.1
4.7
|
L
 264.6%
H
0.4
4.7
|
L
 146.7%
H
0.4
5.9
|
L
 -39.2%
H
0.4
10.1
|
L
 -79.9%
H
0.4
35
|
| Cue Biopharma Inc |
|
34.7
|
0.4
|
L
 11.8%
H
0.3
0.4
|
L
 18.8%
H
0.3
0.4
|
L
 -30.9%
H
0.2
0.6
|
L
 -48.0%
H
0.2
1.0
|
L
 -72.7%
H
0.2
1.8
|
L
 -85.4%
H
0.2
5.1
|
L
 -96.9%
H
0.2
18.4
|
L
H
0.2
31.7
|
| CureVac N.V. |
|
1,049.3
|
4.7
|
L
 -0.2%
H
4.6
4.7
|
L
 8.4%
H
4.3
4.7
|
L
 -9.0%
H
4
5.3
|
L
 -14.5%
H
4
5.6
|
L
 33.5%
H
2.5
5.7
|
L
 -29.2%
H
2.2
12.8
|
L
 -94.5%
H
2.2
133
|
L
H
2.2
151.8
|
| Cadrenal Therapeutics Inc |
|
17.1
|
7.3
|
L
 -0.1%
H
6.9
7.5
|
L
 -1.2%
H
6.4
7.6
|
L
 -34.1%
H
6.4
12.5
|
L
 -48.4%
H
6.4
14.5
|
L
 -51.4%
H
6.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
6.7
|
1.4
|
L
 -2.8%
H
1.4
1.5
|
L
 -7.4%
H
1.4
1.7
|
L
 -24.7%
H
1.3
1.8
|
L
 -71.3%
H
1.2
6.7
|
L
 -98.8%
H
1.2
110.4
|
L
 -99.9%
H
1.2
4212
|
L
 -100.0%
H
1.2
41112
|
L
 -100.0%
H
1.2
784800
|
| Cyclerion Therapeutics Inc |
|
5.3
|
1.4
|
L
 3.0%
H
1.3
1.4
|
L
 2.2%
H
1.2
1.4
|
L
 -18.8%
H
1.2
1.8
|
L
 -44.8%
H
1.2
2.6
|
L
 -57.1%
H
1.2
6.3
|
L
 -89.5%
H
1.2
19.1
|
L
 -97.7%
H
1.2
138
|
L
H
1.2
457
|
| Cytokinetics Inc |
|
7,489.9
|
61.3
|
L
 -0.8%
H
58.9
61.7
|
L
 -2.9%
H
58.9
64.4
|
L
 -7.9%
H
58.9
71.0
|
L
 7.5%
H
54.3
71.0
|
L
 24.1%
H
29.3
71.0
|
L
 43.5%
H
26.0
110
|
L
 213.2%
H
17.7
110
|
L
 512.6%
H
5.8
110
|
| Cellectis (ADR) |
|
455.5
|
4.5
|
L
 -5.4%
H
4.5
4.9
|
L
 -4.4%
H
4.5
5.1
|
L
 -6%
H
3.9
5.5
|
L
 29.7%
H
3.1
5.5
|
L
 170.2%
H
1.1
5.5
|
L
 90.8%
H
1.0
5.5
|
L
 -83.6%
H
1.0
34.7
|
L
 -84.9%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.5
|
1.9
|
L
 4.5%
H
1.8
2.0
|
L
 3.9%
H
1.6
2.0
|
L
 -24.3%
H
1.6
2.8
|
L
 -31.3%
H
1.6
3.6
|
L
 -78.1%
H
1.6
9.8
|
L
 -82.4%
H
1.6
11.2
|
L
 -98.3%
H
1.6
675.2
|
L
H
1.6
736
|
| Compass Pathways PLC (ADR) |
|
629.9
|
6.6
|
L
 0.2%
H
6.3
6.9
|
L
 -1.8%
H
6.3
7.1
|
L
 15.5%
H
5.6
7.2
|
L
 2.0%
H
4.9
7.2
|
L
 47.4%
H
2.3
7.2
|
L
 -15.8%
H
2.3
12.8
|
L
 -85.0%
H
2.3
58.6
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
3,402.8
|
23.0
|
L
 -2.8%
H
22.2
23.7
|
L
 -9.1%
H
22.2
25.7
|
L
 -22.1%
H
22.2
30.6
|
L
 -0.9%
H
17.1
30.6
|
L
 35.3%
H
9.6
30.6
|
L
 601.8%
H
3
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
133.7
|
2.4
|
L
 -4.8%
H
2.4
2.5
|
L
 -10.8%
H
2.4
2.8
|
L
 -5.5%
H
2.0
2.9
|
L
 61.1%
H
1.5
3.3
|
L
 103.4%
H
0.5
3.3
|
L
 179.1%
H
0.5
3.3
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
28.4
|
2.0
|
L
 2.1%
H
2.0
2.0
|
L
 -7.4%
H
1.9
2.1
|
L
 11.2%
H
1.8
2.5
|
L
 -8.7%
H
1.6
2.5
|
L
 -41.0%
H
1.6
9.2
|
L
 -82.5%
H
0.3
16.8
|
L
 -87.3%
H
0.3
46.2
|
L
 -99.5%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
877.9
|
8.6
|
L
 -3.4%
H
8.4
8.9
|
L
 -9.5%
H
8.4
9.6
|
L
 2.5%
H
7.9
10.5
|
L
 7.6%
H
6.9
10.9
|
L
 -32.1%
H
5.6
13.5
|
L
 -59.2%
H
5.6
25.8
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
193.2
|
7.1
|
L
 -4.4%
H
7.0
7.7
|
L
 -10.1%
H
7.0
8.1
|
L
 -8.8%
H
7.0
8.5
|
L
 -2.9%
H
6.9
9.4
|
L
 67.1%
H
3.5
9.4
|
L
 318.8%
H
1.0
9.4
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
7.8
|
L
 0.3%
H
7.4
7.8
|
L
 -3.3%
H
7.4
8.5
|
L
 -13.8%
H
7.3
9.2
|
L
 -10.2%
H
6.6
10
|
L
 -11.1%
H
5.5
13.1
|
L
 -2.9%
H
4.1
14.4
|
L
 -87.7%
H
4.1
138.8
|
L
 -99.9%
H
4.1
19125
|
| DiaMedica Therapeutics Inc |
|
444.7
|
8.5
|
L
 7.7%
H
8.0
8.6
|
L
 3.8%
H
7.7
8.6
|
L
 -1.0%
H
7.7
10.4
|
L
 20.8%
H
5.3
10.4
|
L
 53.6%
H
3.2
10.4
|
L
 489.0%
H
1.3
10.4
|
L
 -14.9%
H
1.1
10.9
|
L
 349.5%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
2,501.7
|
16.0
|
L
 -1.5%
H
15.3
16.5
|
L
 -5.0%
H
15.3
16.9
|
L
 -20.3%
H
15.3
20.6
|
L
 3.9%
H
13.8
20.6
|
L
 -24.7%
H
10.6
24.3
|
L
 -44.6%
H
10.6
33.3
|
L
 -77.4%
H
10.6
84.0
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
76.5
|
4.8
|
L
 4.4%
H
4.5
4.9
|
L
 4.6%
H
4.5
5.1
|
L
 14.1%
H
3.7
5.1
|
L
 -34.4%
H
3.7
7.5
|
L
 346.7%
H
1
13.6
|
L
 35.4%
H
0.8
13.6
|
L
 -67.5%
H
0.8
43.4
|
L
 -96.8%
H
0.8
308.4
|
| DarioHealth Corp |
|
84.8
|
12.6
|
L
 19.3%
H
10.7
13.0
|
L
 25%
H
10.0
13.0
|
L
 4.2%
H
10.0
13.3
|
L
 -23.2%
H
9.0
16.6
|
L
 -29.9%
H
5.9
31
|
L
 -86.2%
H
5.9
135.6
|
L
 -95.9%
H
5.9
637
|
L
 -99.6%
H
5.9
3492
|
| Dermata Therapeutics Inc |
|
7.0
|
2.2
|
L
 0.9%
H
2.1
2.4
|
L
 18.3%
H
1.6
2.7
|
L
 -12.7%
H
1.6
3.0
|
L
 -54.7%
H
1.6
5.9
|
L
 53.9%
H
0.6
7.1
|
L
 -52.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
623.1
|
80.0
|
L
 -4.1%
H
72.0
83.2
|
L
 -2.6%
H
72.0
84.6
|
L
 10.4%
H
72.0
97.8
|
L
 50.2%
H
48.9
97.8
|
L
 100.8%
H
23.2
97.8
|
L
 1739.3%
H
0.9
97.8
|
L
H
0.9
97.8
|
L
H
0.9
97.8
|
| Design Therapeutics Inc |
|
495.0
|
8.7
|
L
 -4.5%
H
8.2
9.1
|
L
 -9.8%
H
8.2
10.0
|
L
 -11.5%
H
8.2
10.3
|
L
 42.2%
H
5.3
10.3
|
L
 30.5%
H
2.6
10.3
|
L
 -8.5%
H
1.9
10.3
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
98.2
|
4.1
|
L
 -0.5%
H
3.9
4.1
|
L
 -3.6%
H
3.9
4.4
|
L
 -18.7%
H
3.9
5.2
|
L
 -25%
H
3.9
8.8
|
L
 -14.6%
H
3.9
8.8
|
L
 200%
H
0.3
19.4
|
L
 -53.5%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Tech Corp |
|
1,751.9
|
15.4
|
L
 0.2%
H
15.4
15.4
|
L
 0.2%
H
15.4
15.4
|
L
 40.6%
H
10.6
15.5
|
L
 52.6%
H
9.7
15.5
|
L
 19.1%
H
9.2
15.5
|
L
 45.8%
H
9.2
15.5
|
L
 233.5%
H
4.5
21.4
|
L
 -33.4%
H
1.8
29.9
|
| Dyne Therapeutics Inc |
|
3,001.6
|
18.2
|
L
 -1.5%
H
17.6
18.6
|
L
 -9.0%
H
17.6
20.2
|
L
 -11.7%
H
17.6
24.0
|
L
 39.6%
H
12.4
25
|
L
 -26.4%
H
6.4
25
|
L
 53.7%
H
6.4
47.5
|
L
 -4.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
681.9
|
17.0
|
L
 -10.8%
H
16.8
19.0
|
L
 -11.4%
H
16.8
19.9
|
L
 30.2%
H
13.0
26.2
|
L
 31.7%
H
12.6
26.2
|
L
 405.7%
H
3.3
26.2
|
L
 13.3%
H
0.5
26.2
|
L
 -38.2%
H
0.5
73.8
|
L
 -95.2%
H
0.5
505.7
|
| Editas Medicine Inc |
|
194.3
|
2.0
|
L
 -2.9%
H
2.0
2.1
|
L
 -8.3%
H
2.0
2.1
|
L
 -18.1%
H
2.0
2.7
|
L
 -49.2%
H
2.0
4.5
|
L
 48.5%
H
0.9
4.5
|
L
 -78.5%
H
0.9
11.9
|
L
 -97.2%
H
0.9
100.0
|
L
H
0.9
100.0
|
| Edesa Biotech Inc |
|
12.3
|
1.5
|
L
 -1.3%
H
1.4
1.5
|
L
 2.8%
H
1.3
1.6
|
L
 -12.4%
H
1.3
1.8
|
L
 -42.2%
H
1.3
3.0
|
L
 -21.3%
H
1.3
4.5
|
L
 -90.7%
H
1.3
19.7
|
L
 -95.1%
H
1.3
84
|
L
 -99.9%
H
1.3
2037.4
|
| Eledon Pharma Inc |
|
123.8
|
1.7
|
L
 1.9%
H
1.6
1.7
|
L
 3.1%
H
1.4
1.7
|
L
 3.8%
H
1.4
1.8
|
L
 -41.9%
H
1.4
4.6
|
L
 -63.3%
H
1.4
5.0
|
L
 -37.0%
H
1.1
5.4
|
L
 -88.7%
H
1.1
22.9
|
L
 -99.9%
H
1.1
1425.6
|
| Elicio Therapeutics Inc |
|
135.7
|
7.9
|
L
 -2.4%
H
7.8
8.2
|
L
 -2.6%
H
7.8
8.3
|
L
 -5.5%
H
7.7
9
|
L
 -28.8%
H
7.4
11.5
|
L
 39.9%
H
4.6
12.6
|
L
 -10.9%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
902.7
|
15.2
|
L
 -2.1%
H
14.9
15.7
|
L
 -6.7%
H
14.9
16.4
|
L
 -28.9%
H
14.9
22.1
|
L
 -22.4%
H
14.9
24.6
|
L
 -37.7%
H
13.3
25.1
|
L
 -10.5%
H
9.8
30.0
|
L
 -84.1%
H
3.9
96.4
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
169.0
|
3.5
|
L
 -5.6%
H
3.5
3.8
|
L
 -28.2%
H
3.5
4.9
|
L
 104.6%
H
1.7
5.1
|
L
 78.8%
H
1.5
5.1
|
L
 58.7%
H
1.1
5.1
|
L
 -12.6%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
185.2
|
0.8
|
L
 2.6%
H
0.8
0.8
|
L
 4%
H
0.7
0.8
|
L
 -32.8%
H
0.7
1.2
|
L
 -26.4%
H
0.7
1.8
|
L
 -38.1%
H
0.7
2.1
|
L
 -80.9%
H
0.7
4.7
|
L
 -91.9%
H
0.7
29.4
|
L
 -99.5%
H
0.7
318
|
| Enochian Biosciences Inc |
|
-
|
0.9
|
L
 -3.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1.0
|
L
 -27.7%
H
0.9
1.4
|
L
 -33.8%
H
0.8
1.7
|
L
 193.8%
H
0.1
1.7
|
L
 -24.8%
H
0.1
2.3
|
L
 -70.3%
H
0.1
13.8
|
L
 -75.9%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.8
|
1.0
|
L
 10.6%
H
1.0
1.1
|
L
 -5.5%
H
0.9
1.1
|
L
 -36.2%
H
0.9
1.7
|
L
 -59.1%
H
0.9
2.8
|
L
 -88.6%
H
0.9
9.3
|
L
 -89.3%
H
0.1
18.4
|
L
 -100.0%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
401.5
|
13.9
|
L
 -3.5%
H
13.7
14.8
|
L
 -17.5%
H
13.7
17.2
|
L
 -1.3%
H
13.7
17.2
|
L
 34.7%
H
10.2
17.2
|
L
 148.8%
H
4.1
17.2
|
L
 -70.0%
H
4.1
62.1
|
L
 -67.0%
H
4.1
102
|
L
 -59.3%
H
4.1
127.8
|
| Entera Bio Ltd |
|
81.2
|
1.8
|
L
H
1.8
1.8
|
L
 2.9%
H
1.5
2.0
|
L
 -16.1%
H
1.5
2.3
|
L
 -6.8%
H
1.5
3.2
|
L
 -34.2%
H
1.5
3.2
|
L
 62.4%
H
0.5
3.4
|
L
 42.7%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
4.1
|
4.0
|
L
 9.8%
H
3.7
4.1
|
L
 -2.0%
H
3.5
4.3
|
L
 -34.0%
H
3.5
13.3
|
L
 -51.5%
H
3.5
13.3
|
L
 -94.7%
H
3.5
81
|
L
 -99.2%
H
3.5
1256.4
|
L
 -100.0%
H
3.5
63000
|
L
 -100.0%
H
3.5
12150000
|
| Evolus Inc |
|
392.2
|
6.1
|
L
 -10.0%
H
6.0
6.7
|
L
 -12.3%
H
6.0
6.9
|
L
 -11.2%
H
6.0
7.3
|
L
 -6.9%
H
5.9
7.8
|
L
 -47.5%
H
5.7
17.1
|
L
 -28.1%
H
5.7
17.8
|
L
 89.1%
H
3.1
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
95.6
|
1.6
|
L
 2.6%
H
1.5
1.6
|
L
 4.7%
H
1.4
1.7
|
L
 80.5%
H
0.8
1.7
|
L
 18.1%
H
0.8
1.7
|
L
 101.3%
H
0.3
2.4
|
L
 33.1%
H
0.3
3.3
|
L
 -68.8%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Erasca Inc |
|
990.2
|
3.5
|
L
 -2.8%
H
3.4
3.7
|
L
 0.3%
H
3.4
3.8
|
L
 9.4%
H
3.1
3.8
|
L
 44.2%
H
2.1
3.8
|
L
 27.4%
H
1.0
3.8
|
L
 -21.4%
H
1.0
4.6
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
903.2
|
3.8
|
L
 2.7%
H
3.6
3.9
|
L
 -5.7%
H
3.6
4.0
|
L
 0.5%
H
3.6
4.1
|
L
 15.5%
H
2.3
4.1
|
L
 74.0%
H
0.7
4.1
|
L
 -36.7%
H
0.7
7.4
|
L
 -86.3%
H
0.7
39.5
|
L
 -82.4%
H
0.7
82.7
|
| Eton Pharma Inc |
|
448.7
|
16.7
|
L
 2.9%
H
16
16.8
|
L
 -0.6%
H
15.8
17.3
|
L
 -0.5%
H
15.8
17.3
|
L
 -16.1%
H
15.3
21.9
|
L
 28.7%
H
11.1
23
|
L
 476.9%
H
2.4
23
|
L
 106.3%
H
2.0
23
|
L
H
2.0
23
|
| Edgewise Therapeutics Inc |
|
2,495.3
|
23.6
|
L
 -0.8%
H
23.0
23.9
|
L
 -10.6%
H
23.0
26.5
|
L
 -0.6%
H
19.8
27.4
|
L
 50.6%
H
14.3
27.4
|
L
 -15.0%
H
10.6
30.5
|
L
 150.7%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
11,368.0
|
42.4
|
L
 -2.7%
H
41.9
43.5
|
L
 -8.3%
H
41.9
46.3
|
L
 -4.4%
H
40.7
47.2
|
L
 5.8%
H
33.8
47.2
|
L
 24.8%
H
31.9
49.6
|
L
 149.0%
H
16.2
49.6
|
L
 106.5%
H
14.9
49.6
|
L
 672.3%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
32.4
|
4.0
|
L
 10.6%
H
3.8
4.1
|
L
 3.1%
H
3.3
4.1
|
L
 -0.3%
H
2.9
4.4
|
L
 -64.2%
H
2.9
11.4
|
L
 -55.1%
H
0.0
17.2
|
L
 -97.4%
H
0.0
468
|
L
 -99.2%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,443.0
|
17.4
|
L
 -0.3%
H
16.7
17.5
|
L
 -4.7%
H
16.7
18.5
|
L
 4.3%
H
15.8
19.1
|
L
 27.0%
H
9.7
19.1
|
L
 111.0%
H
3.9
19.1
|
L
 423.4%
H
2.2
31.0
|
L
 93.5%
H
2.2
31.0
|
L
 -63.7%
H
2.2
48.2
|
| Evaxion Biotech A/S (ADR) |
|
40.0
|
4.8
|
L
 1.9%
H
4.6
4.9
|
L
 -6.4%
H
4.6
5.2
|
L
 -9.3%
H
4.6
6.9
|
L
 -11.6%
H
4.6
12.2
|
L
 427.5%
H
0.8
12.2
|
L
 -72.6%
H
0.8
21.1
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
1,133.1
|
3.2
|
L
 0.3%
H
3.1
3.2
|
L
 2.6%
H
3.1
3.2
|
L
 -1.2%
H
2.9
3.2
|
L
 -20.5%
H
2.9
4.3
|
L
 -27.2%
H
2.8
4.8
|
L
 -60.9%
H
2.8
13.5
|
L
 -82.6%
H
2.8
26.6
|
L
 41.2%
H
1.6
26.6
|
| Fate Therapeutics Inc |
|
116.5
|
1.0
|
L
 2.0%
H
1.0
1.0
|
L
 1%
H
1.0
1.0
|
L
 -8.2%
H
1.0
1.2
|
L
 -16.5%
H
1.0
1.9
|
L
 -44.5%
H
0.7
2.0
|
L
 -90.9%
H
0.7
11.4
|
L
 -98.9%
H
0.7
121.2
|
L
 -69.3%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
132.5
|
4.3
|
L
 6.0%
H
4.1
4.3
|
L
 14.2%
H
3.5
4.3
|
L
 55.3%
H
2.8
4.3
|
L
 55.3%
H
2.4
4.3
|
L
 91.5%
H
1.3
4.3
|
L
 -59.3%
H
1.2
17.4
|
L
 -91.2%
H
1.2
91.5
|
L
 -89.7%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
282.6
|
22.6
|
L
 -4.5%
H
21.9
25.4
|
L
 -19.1%
H
21.9
29.3
|
L
 9.7%
H
18.9
31.3
|
L
 45.6%
H
10.3
31.3
|
L
 -7.9%
H
4.9
31.3
|
L
 -11.5%
H
4.1
32.3
|
L
 -97.4%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
417.1
|
7.3
|
L
 -0.3%
H
7.0
7.5
|
L
 -8.4%
H
7.0
7.9
|
L
 -34.8%
H
7.0
11.8
|
L
 -14.6%
H
7.0
12.3
|
L
 22.9%
H
2.2
12.3
|
L
 -66.5%
H
2.2
36.3
|
L
 -80.6%
H
2.2
55.1
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
256.2
|
7.5
|
L
 -2.3%
H
7.4
7.8
|
L
 -7.3%
H
7.4
8.2
|
L
 -3.6%
H
7.4
8.2
|
L
 -24.1%
H
7.4
9.9
|
L
 22.0%
H
4.7
9.9
|
L
 -26.8%
H
4.0
11.9
|
L
 0.5%
H
3.8
11.9
|
L
 331.0%
H
1.1
15.0
|
| FibroGen Inc |
|
36.1
|
8.9
|
L
 -2.5%
H
8.8
9.3
|
L
 0.3%
H
8.5
9.3
|
L
 8.2%
H
8.2
10.5
|
L
 -23.9%
H
8.0
12.1
|
L
 -34.6%
H
4.9
22.0
|
L
 -97.8%
H
4.5
642.3
|
L
 -99.0%
H
4.5
1430.2
|
L
 -98.8%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
281.6
|
5.0
|
L
 -4.1%
H
5.0
5.3
|
L
 -7.8%
H
5.0
5.5
|
L
 8.7%
H
4.2
6.0
|
L
 7.3%
H
3.3
6.0
|
L
 3.5%
H
2.9
6.8
|
L
 -23.7%
H
2.7
10.2
|
L
 -73.9%
H
2.7
25.1
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
41.5
|
3.4
|
L
 -2.0%
H
3.3
3.5
|
L
 5.3%
H
3.1
3.5
|
L
 -6.9%
H
2.7
3.7
|
L
 62.8%
H
1.9
6.4
|
L
 -1.8%
H
1.3
6.4
|
L
 -85.6%
H
1.3
53.8
|
L
 -98.4%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Flora Growth Corp |
|
5.5
|
7.4
|
L
 8.2%
H
6.7
7.4
|
L
 1.8%
H
5.9
7.6
|
L
 -29.1%
H
5.9
11.2
|
L
 -60.9%
H
5.9
20.5
|
L
 -82.7%
H
5.9
47
|
L
 -96.2%
H
5.9
464.3
|
L
H
5.9
16731
|
L
H
5.9
16731
|
| Amicus Therapeutics Inc |
|
4,407.6
|
14.3
|
L
 -0.1%
H
14.2
14.3
|
L
H
14.2
14.3
|
L
 43.2%
H
9.7
14.4
|
L
 73.8%
H
7.9
14.4
|
L
 51.9%
H
5.5
14.4
|
L
 18.5%
H
5.5
14.6
|
L
 -34.6%
H
5.5
24.8
|
L
 57.8%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
8
|
L
 -0.6%
H
7.8
8.1
|
L
 -1.5%
H
7.7
8.1
|
L
 17.5%
H
6.7
8.8
|
L
 -82.7%
H
5.2
55.9
|
L
 -47.1%
H
5.2
55.9
|
L
 -95.4%
H
5.2
279.5
|
L
 -99.5%
H
5.2
2918.5
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
715.1
|
10.8
|
L
 -0.7%
H
10.5
11.0
|
L
 -6.4%
H
10.5
12.3
|
L
 23.7%
H
8.6
15.7
|
L
 17.6%
H
7.3
15.7
|
L
 113.4%
H
2.3
15.7
|
L
 30.9%
H
2.3
15.7
|
L
 -12.7%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
7.6
|
4.9
|
L
 -5.6%
H
4.7
5.3
|
L
 62.8%
H
2.8
5.3
|
L
 89.5%
H
1.9
5.3
|
L
 11.5%
H
1.9
5.8
|
L
 1054.8%
H
0.4
5.8
|
L
 -96.9%
H
0.4
179.2
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
250.2
|
3.9
|
L
 -4.2%
H
3.8
4.2
|
L
 -4.2%
H
3.8
4.4
|
L
 -38.4%
H
3.5
7.1
|
L
 -10.4%
H
3.5
7.1
|
L
 234.5%
H
1.1
7.1
|
L
 226.1%
H
0.7
7.1
|
L
 74.8%
H
0.7
7.1
|
L
 139.5%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
114.2
|
3.0
|
L
 -6.6%
H
2.8
3.3
|
L
 -5.7%
H
2.8
3.3
|
L
 -15.1%
H
2.1
4.3
|
L
 54.7%
H
1.7
4.3
|
L
 22.2%
H
1.4
4.3
|
L
 -8.6%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| Generation Bio Co |
|
36.4
|
5.4
|
L
 -0.7%
H
5.3
5.5
|
L
 -3.6%
H
5.3
5.8
|
L
 3.5%
H
5.2
5.8
|
L
 -14.8%
H
4.9
6.9
|
L
 -53.0%
H
3
11.9
|
L
 -89.4%
H
3
73.5
|
L
 -98.2%
H
3
418.6
|
L
H
3
557.2
|
| CytoMed Therapeutics Ltd |
|
16.0
|
1.4
|
L
 -2.2%
H
1.3
1.4
|
L
 -11.1%
H
1.3
1.6
|
L
 -26.5%
H
1.3
2.1
|
L
 -32.3%
H
1.3
3.7
|
L
 -60.6%
H
1.3
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
| Geron Corp |
|
842.6
|
1.3
|
L
H
1.3
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 3.9%
H
1.2
1.5
|
L
 -2.2%
H
1.0
1.5
|
L
 -63.0%
H
1.0
3.6
|
L
 -58.6%
H
1.0
5.3
|
L
 -19.0%
H
1.0
5.3
|
L
 -71.2%
H
0.8
7.0
|
| GH Research PLC |
|
959.0
|
15.5
|
L
 16.8%
H
15
19
|
L
 22.7%
H
12.4
19
|
L
 0.7%
H
12.0
19
|
L
 18.0%
H
12.0
19
|
L
 71.2%
H
8.0
20.5
|
L
 57.8%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
146,772.4
|
118.3
|
L
 -2.7%
H
116.9
121
|
L
 -5.1%
H
116.9
125.3
|
L
 -3.5%
H
116.9
127.4
|
L
 5.0%
H
112.4
128.7
|
L
 29.4%
H
88.6
128.7
|
L
 38.4%
H
62.1
128.7
|
L
 96.8%
H
57.2
128.7
|
L
 20.7%
H
56.6
128.7
|
| Galmed Pharma Ltd |
|
4.6
|
0.8
|
L
 2.4%
H
0.8
0.9
|
L
 -2.3%
H
0.7
0.9
|
L
 -25.7%
H
0.7
1.2
|
L
 -46.5%
H
0.7
1.7
|
L
 -75.8%
H
0.7
3.6
|
L
 -99.4%
H
0.2
170.1
|
L
 -99.9%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
293.9
|
21.2
|
L
 8.9%
H
18.7
21.9
|
L
 2.6%
H
18.5
30.8
|
L
 141.0%
H
8.8
30.8
|
L
 94.4%
H
7.8
30.8
|
L
 71.3%
H
7.8
30.8
|
L
 50.9%
H
7.6
30.8
|
L
 -39.3%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Galecto Inc |
|
34.0
|
21.3
|
L
 -2.6%
H
20.8
22.6
|
L
 -37.7%
H
20.8
35.1
|
L
 -7.1%
H
20.8
38.3
|
L
 461.0%
H
3.6
38.3
|
L
 285.1%
H
2.0
38.3
|
L
 1366.2%
H
0.5
38.3
|
L
 63.5%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
937.7
|
14.4
|
L
 -5.9%
H
13.8
15.5
|
L
 -16.7%
H
13.8
17.2
|
L
 -16.6%
H
13.8
19.2
|
L
 86.1%
H
7.2
19.2
|
L
 100.8%
H
3.5
19.2
|
L
 85.8%
H
2.4
19.2
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
717.0
|
11.1
|
L
 0.3%
H
10.9
11.6
|
L
 -10.0%
H
10.9
12.6
|
L
 -14.5%
H
10.9
15.6
|
L
 -5.2%
H
9.8
16.4
|
L
 -59.9%
H
9.8
37
|
L
 -96.2%
H
9.8
416
|
L
 -97.0%
H
9.8
440
|
L
 -98.1%
H
9.8
2605
|
| Genelux Corp |
|
132.4
|
3.5
|
L
 -23.5%
H
3.4
5.0
|
L
 -20.4%
H
3.4
5.0
|
L
 -25.2%
H
3.4
5.0
|
L
 -21.8%
H
3.4
8.5
|
L
 43.2%
H
2.0
8.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
4.1
|
1.8
|
L
 0.6%
H
1.8
1.9
|
L
 0.6%
H
1.7
1.9
|
L
 -46.3%
H
1.7
3.5
|
L
 847.4%
H
0.2
13.0
|
L
 114.3%
H
0.1
13.0
|
L
 3.4%
H
0.1
13.0
|
L
 -56.4%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
634.2
|
2.7
|
L
 -4.9%
H
2.7
3.0
|
L
 -15.2%
H
2.7
3.4
|
L
 -17.5%
H
2.7
3.9
|
L
 6.6%
H
2.1
3.9
|
L
 168.6%
H
0.8
3.9
|
L
 27.4%
H
0.5
3.9
|
L
 -72.8%
H
0.5
15.2
|
L
H
0.5
27.2
|
| Geovax Labs Inc |
|
8.2
|
0.2
|
L
 -9.5%
H
0.2
0.2
|
L
 5.6%
H
0.2
0.2
|
L
 -50%
H
0.1
0.4
|
L
 -67.2%
H
0.1
0.6
|
L
 -92.8%
H
0.1
2.7
|
L
 -70.8%
H
0.1
11.1
|
L
 -94.3%
H
0.1
11.1
|
L
 -100.0%
H
0.1
1000000
|
| Graphite Bio Inc |
|
959.7
|
16.5
|
L
 3%
H
15.9
16.8
|
L
 -2.3%
H
15.4
17
|
L
 -40.9%
H
15.4
28.1
|
L
 -66.2%
H
15.4
49.3
|
L
 -38.5%
H
15.4
50.4
|
L
 -89.4%
H
15.4
413
|
L
H
15.4
1666
|
L
H
15.4
1666
|
| GT Biopharma Inc |
|
8.5
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -3.6%
H
0.8
0.9
|
L
 27.0%
H
0.6
0.9
|
L
 25%
H
0.5
1.4
|
L
 -73.3%
H
0.5
3.9
|
L
 -21.6%
H
0.2
10.7
|
L
 -89.1%
H
0.2
19.7
|
L
 -100.0%
H
0.2
18870
|
| Galapagos NV (ADR) |
|
2,157.5
|
32.7
|
L
 -0.7%
H
31.7
32.9
|
L
 -0.9%
H
31.7
33.4
|
L
 3.1%
H
30.7
33.4
|
L
 -13.0%
H
29.8
37
|
L
 15.2%
H
22.4
37.8
|
L
 -25.2%
H
22.4
48.1
|
L
 -66.9%
H
22.4
113.7
|
L
 -46.3%
H
22.4
274.0
|
| Genmab (ADR) |
|
19,588.6
|
31.8
|
L
 -0.1%
H
31.3
32.1
|
L
 -4.9%
H
30.4
33
|
L
 -0.7%
H
30.4
34.0
|
L
 -5.2%
H
28.1
34.0
|
L
 48.1%
H
17.2
34.0
|
L
 -25.2%
H
17.2
43.7
|
L
 -22.0%
H
17.2
49.1
|
L
 136.4%
H
9.2
49.1
|
| Genenta Science SpA (ADR) |
|
33.7
|
1.4
|
L
 2.1%
H
1.4
1.5
|
L
 -1.4%
H
1.3
1.7
|
L
 -22.6%
H
1.3
2.1
|
L
 -56.4%
H
1.3
10
|
L
 -66.8%
H
1.3
10
|
L
 -74.2%
H
1.3
10
|
L
H
1.3
13.1
|
L
H
1.3
13.1
|
| Grifols SA (ADR) - Level III |
|
6,342.3
|
9.3
|
L
 0.9%
H
9.3
9.4
|
L
 2.4%
H
9.0
9.5
|
L
 4.8%
H
8.7
9.5
|
L
 -6.3%
H
7.6
9.9
|
L
 20.6%
H
6.2
11.1
|
L
 1.3%
H
5.3
12.2
|
L
 -50.8%
H
5.3
20.5
|
L
 -41.7%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
8,372.9
|
71.2
|
L
 1.3%
H
69.2
71.6
|
L
 3.4%
H
67.0
71.6
|
L
 13.1%
H
61.2
71.6
|
L
 3.2%
H
61.2
74.3
|
L
 48.9%
H
47.5
79.5
|
L
 32.1%
H
29.9
79.5
|
L
 67.9%
H
29.9
79.5
|
L
 327.9%
H
7.0
79.5
|
| HCW Biologics Inc |
|
3.0
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -21.8%
H
1.0
1.4
|
L
 -45.6%
H
1.0
2.2
|
L
 -72.5%
H
1.0
4.9
|
L
 -93.7%
H
0.2
41.2
|
L
 -98.6%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
37.4
|
3.2
|
L
 -5.6%
H
3.0
3.4
|
L
 23.2%
H
2.6
3.6
|
L
 29.2%
H
2.2
3.6
|
L
 9.6%
H
2.2
6.9
|
L
 139.9%
H
1.1
9.1
|
L
 -69.6%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
16.4
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 5.0%
H
1.0
1.1
|
L
 -10.9%
H
1.0
1.3
|
L
 -32.9%
H
1.0
1.8
|
L
 35.9%
H
0.7
3.8
|
L
 -83.8%
H
0.6
7.8
|
L
 -98.3%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
31.1
|
0.6
|
L
H
0.6
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -36%
H
0.6
1.2
|
L
 -68.8%
H
0.6
2.2
|
L
 -61.9%
H
0.6
2.4
|
L
 -67.7%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,116.7
|
36.8
|
L
 -1.7%
H
35.4
37.3
|
L
 -3.6%
H
35.4
38.2
|
L
 -3.9%
H
35.4
40.9
|
L
 34.7%
H
25.5
40.9
|
L
 4.2%
H
25.5
40.9
|
L
 -31.7%
H
18.6
55.6
|
L
 3.7%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
2,029.7
|
54.8
|
L
 9.8%
H
50.7
54.8
|
L
 9.4%
H
46.6
54.8
|
L
 17.2%
H
44
54.8
|
L
 20.6%
H
32.6
54.8
|
L
 50.8%
H
20.9
54.8
|
L
 278.2%
H
7.6
59.2
|
L
 645.6%
H
5.4
59.2
|
L
 705.9%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
227.4
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -3.1%
H
1.2
1.4
|
L
 -5.3%
H
1.1
1.4
|
L
 -6.1%
H
1
1.4
|
L
 -25.3%
H
1
2.7
|
L
 -53.2%
H
0.5
3.9
|
L
 -94.0%
H
0.5
20.8
|
L
 -95.1%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
27.8
|
7.2
|
L
 3.1%
H
6.9
7.5
|
L
 -12.9%
H
6.5
8.4
|
L
 -27.7%
H
6.5
11.5
|
L
 -60.8%
H
5.6
18.9
|
L
 80.3%
H
2.9
38.3
|
L
 -86.1%
H
2.7
136.5
|
L
 -93.3%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
198.5
|
1.1
|
L
 8.2%
H
1.0
1.1
|
L
 -0.9%
H
0.9
1.1
|
L
 -18.5%
H
0.9
1.3
|
L
 -49.5%
H
0.9
2.6
|
L
 -79.2%
H
0.9
5.3
|
L
 -50.5%
H
0.9
10.0
|
L
 -89.6%
H
0.9
17.5
|
L
H
0.9
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,298.3
|
13.4
|
L
 -2.1%
H
13.2
13.8
|
L
 -2.9%
H
13.1
13.9
|
L
 -5.6%
H
13.1
14.3
|
L
 -16.9%
H
13.1
16.4
|
L
 -10.8%
H
11.5
19.5
|
L
 -26.7%
H
10.7
21.9
|
L
 -60.7%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
2,048.7
|
2.1
|
L
 3.0%
H
2.0
2.1
|
L
 -2.8%
H
2.0
2.1
|
L
 -9.6%
H
2.0
2.5
|
L
 -18.1%
H
2.0
2.7
|
L
 -26.0%
H
1.8
4.3
|
L
 -55.6%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Immucell Corp |
|
54.7
|
6.1
|
L
 2.2%
H
5.8
6.1
|
L
 -1.1%
H
5.8
6.5
|
L
 16.1%
H
5.2
7.1
|
L
 -4.1%
H
4.5
7.1
|
L
 17.5%
H
4.3
7.6
|
L
 -4.0%
H
3.3
7.8
|
L
 -0.8%
H
3.3
13.2
|
L
 -18.6%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,063.1
|
34.9
|
L
 3.2%
H
32.6
35.0
|
L
 -0.7%
H
32.6
35.3
|
L
 -3.0%
H
32.6
37.1
|
L
 26.4%
H
26.1
37.1
|
L
 35.2%
H
13.5
37.1
|
L
 100.1%
H
13.3
47.7
|
L
 159.0%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
77.2
|
1.1
|
L
 4.6%
H
1.1
1.2
|
L
 3.6%
H
1.0
1.2
|
L
 3.6%
H
1.0
1.2
|
L
 -27.9%
H
0.9
1.9
|
L
 -52.7%
H
0.7
2.8
|
L
 -63.2%
H
0.7
7.3
|
L
 -77.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
71.7
|
6.4
|
L
 -5.2%
H
6.4
6.9
|
L
 10.5%
H
5.7
7.2
|
L
 -5.5%
H
5.7
7.2
|
L
 -25.5%
H
5.7
9.1
|
L
 -68.4%
H
5.7
20.4
|
L
 -82.1%
H
5.7
91.7
|
L
H
5.7
451.3
|
L
H
5.7
451.3
|
| Inhibikase Therapeutics Inc |
|
243.7
|
2.0
|
L
 3.1%
H
2.0
2.2
|
L
 0.5%
H
1.9
2.2
|
L
 33.1%
H
1.4
2.2
|
L
 21.1%
H
1.3
2.2
|
L
 -37.2%
H
1.3
3.5
|
L
 -39.6%
H
0.8
6.9
|
L
 -95.2%
H
0.8
55.0
|
L
H
0.8
70.8
|
| Illumina Inc |
|
21,595.2
|
141.3
|
L
 5.2%
H
134.4
141.5
|
L
 4.7%
H
130.4
141.5
|
L
 10.4%
H
126.4
141.5
|
L
 38.4%
H
88
141.5
|
L
 3.9%
H
68.7
153.1
|
L
 -30.2%
H
68.7
238.6
|
L
 -61.6%
H
68.7
555.8
|
L
 -22.0%
H
68.7
555.8
|
| IM Cannabis Corp |
|
7.6
|
1.5
|
L
 -2.7%
H
1.4
1.6
|
L
 1.4%
H
1.3
1.6
|
L
 -19.0%
H
1.3
2.1
|
L
 -27.1%
H
0.9
2.6
|
L
 -42.7%
H
0.9
7.1
|
L
 -76.1%
H
0.4
11.0
|
L
 -99.7%
H
0.4
697.8
|
L
H
0.4
697.8
|
| Immix Biopharma Inc |
|
268.7
|
5.1
|
L
 -6.1%
H
5.1
5.6
|
L
 -9.6%
H
5.0
5.8
|
L
 5.4%
H
4.5
7.7
|
L
 147.6%
H
2
7.7
|
L
 117.0%
H
1.3
7.7
|
L
 117.0%
H
1.3
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immunome Inc |
|
2,174.7
|
19.7
|
L
 -5.3%
H
19.3
20.9
|
L
 -9.2%
H
19.3
22.1
|
L
 -1.9%
H
18.8
25.3
|
L
 59.2%
H
12.4
25.3
|
L
 78.2%
H
5.2
25.3
|
L
 418.7%
H
3.7
31.0
|
L
 102.2%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
13.4
|
4.0
|
L
H
3.9
4.2
|
L
 25.4%
H
3.0
4.2
|
L
 -1.3%
H
3.0
4.4
|
L
 -26.4%
H
3.0
5.4
|
L
 -73.1%
H
3.0
47.4
|
L
 -84.2%
H
3.0
54.8
|
L
 -97.8%
H
3.0
783
|
L
 -99.9%
H
3.0
6110.7
|
| Immuneering Corp (Class A) |
|
426.8
|
6.6
|
L
 -0.2%
H
6.3
6.8
|
L
 -1.8%
H
6.3
7.0
|
L
 -1.2%
H
5.5
7.0
|
L
 9.3%
H
5.2
7.8
|
L
 182.5%
H
1.1
10.1
|
L
 64.8%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,307.1
|
9.8
|
L
 -6.7%
H
9.1
10.6
|
L
 -4.6%
H
9.1
10.9
|
L
 -17.9%
H
9.1
11.0
|
L
 3.7%
H
8.7
12.4
|
L
 36.0%
H
3.3
12.4
|
L
 9.2%
H
3.3
13.8
|
L
 -11.4%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunic Inc |
|
77.0
|
0.6
|
L
 10.3%
H
0.6
0.7
|
L
 14.3%
H
0.5
0.7
|
L
 -7.3%
H
0.5
0.7
|
L
 -34.7%
H
0.5
1
|
L
 -40.7%
H
0.5
1.4
|
L
 -54.0%
H
0.5
3.2
|
L
 -96.0%
H
0.5
28.2
|
L
 -99.8%
H
0.5
425.6
|
| Immunovant Inc |
|
5,030.9
|
25.0
|
L
 -3.6%
H
24.7
25.9
|
L
 -4.6%
H
24.7
26.6
|
L
 9.0%
H
22.3
27.7
|
L
 47.8%
H
16.0
27.7
|
L
 0.6%
H
12.7
27.7
|
L
 35.0%
H
12.7
45.6
|
L
 -45.0%
H
3.1
50.3
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
24.1
|
2.5
|
L
 0.4%
H
2.4
2.5
|
L
 10.8%
H
1.9
2.6
|
L
 35.7%
H
1.2
2.6
|
L
 3.4%
H
1.2
2.7
|
L
 782.1%
H
0.1
4.2
|
L
 -10.5%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,642.4
|
76.9
|
L
 2.5%
H
74.8
77.5
|
L
 -4.2%
H
74.5
82.3
|
L
 -12.1%
H
74.5
94.6
|
L
 115.7%
H
28.2
94.6
|
L
 381.4%
H
10.8
94.6
|
L
 215.5%
H
10.8
94.6
|
L
 145.9%
H
7.7
94.6
|
L
H
7.7
94.6
|
| Incyte |
|
19,983.7
|
101.8
|
L
 0.4%
H
99.0
103.0
|
L
 1.7%
H
97.6
103.0
|
L
 1.3%
H
93.5
103.7
|
L
 17.2%
H
82.8
109.3
|
L
 46.2%
H
53.6
109.3
|
L
 28.7%
H
50.3
109.3
|
L
 17.7%
H
50.3
109.3
|
L
 -1.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
4.4
|
2.5
|
L
 -8.0%
H
2.5
2.7
|
L
 -1.2%
H
2.2
3.1
|
L
 17.8%
H
1.9
3.2
|
L
 -22.9%
H
1.7
5.3
|
L
 186.4%
H
0.3
13.4
|
L
 55.6%
H
0.3
13.4
|
L
 -82.6%
H
0.3
36.8
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
4,532.1
|
36.3
|
L
 1.5%
H
34.5
36.3
|
L
 0.1%
H
34.5
36.5
|
L
 4.8%
H
34.4
38
|
L
 56.5%
H
22.6
38
|
L
 190.2%
H
7.6
38
|
L
 66.7%
H
7.3
38
|
L
 2489.3%
H
1.4
38
|
L
 1267.9%
H
0.4
38
|
| MiNK Therapeutics Inc |
|
56.6
|
12.1
|
L
 8.5%
H
11.0
12.1
|
L
 0.9%
H
10.8
12.1
|
L
 -2.4%
H
10.8
13.3
|
L
 -19.7%
H
10.5
16
|
L
 36.0%
H
0.9
76
|
L
 -49.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
3.2
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 -5.7%
H
1.0
1.2
|
L
 -14.2%
H
1.0
1.5
|
L
 -49.8%
H
1.0
2.5
|
L
 -76.9%
H
1.0
8.3
|
L
 -97.4%
H
1.0
55.4
|
L
 -99.9%
H
1.0
3210
|
L
 -99.9%
H
1.0
32175
|
| INmune Bio Inc |
|
39.6
|
1.5
|
L
 -3.3%
H
1.5
1.6
|
L
 -13.9%
H
1.5
1.7
|
L
 -20.7%
H
1.5
2.3
|
L
 -28.4%
H
1.4
2.3
|
L
 -71.9%
H
1.4
11.6
|
L
 -78.3%
H
1.4
14.7
|
L
 -91.6%
H
1.4
30.4
|
L
H
1.4
30.4
|
| Inovio Pharma Inc |
|
109.2
|
1.6
|
L
 -5.9%
H
1.6
1.7
|
L
 -30.6%
H
1.6
1.9
|
L
 -21.3%
H
1.6
2.7
|
L
 -34.6%
H
1.6
2.7
|
L
 -12.6%
H
1.3
3.0
|
L
 -2.5%
H
0.3
14.8
|
L
 -83.7%
H
0.3
19
|
L
 -75.2%
H
0.3
33.8
|
| Insmed Inc |
|
37,365.5
|
175.2
|
L
 -1.1%
H
167.4
176.1
|
L
 -1.5%
H
167.4
178.5
|
L
 -14.6%
H
161.0
206.7
|
L
 11.5%
H
154.8
212.8
|
L
 150.8%
H
60.4
212.8
|
L
 782.6%
H
16.0
212.8
|
L
 424.2%
H
16.0
212.8
|
L
 916.2%
H
9.0
212.8
|
| Innoviva Inc |
|
1,497.6
|
20.0
|
L
 0.8%
H
19.4
20.2
|
L
 1.2%
H
19.4
20.2
|
L
 -3.7%
H
19.3
21.4
|
L
 14.6%
H
16.5
22.8
|
L
 14.3%
H
16.5
22.8
|
L
 51.4%
H
10.6
22.8
|
L
 60.5%
H
10.6
22.8
|
L
 94.1%
H
7.6
22.8
|
| IO Biotech Inc |
|
43.9
|
0.6
|
L
 -9.0%
H
0.6
0.7
|
L
 -17.6%
H
0.6
0.7
|
L
 -10.3%
H
0.6
0.9
|
L
 27.1%
H
0.5
1.2
|
L
 -35.1%
H
0.3
2.8
|
L
 -76.2%
H
0.3
3.3
|
L
H
0.3
17.9
|
L
H
0.3
17.9
|
| Ionis Pharma Inc |
|
12,719.8
|
78.5
|
L
 -1.4%
H
76.1
79.4
|
L
 -1.8%
H
76.1
80.2
|
L
 -4.0%
H
76.1
82.9
|
L
 13.6%
H
66.7
83.6
|
L
 125.6%
H
24.0
83.6
|
L
 100.1%
H
24.0
83.6
|
L
 38.3%
H
24.0
83.6
|
L
 27.3%
H
19.6
86.6
|
| Iovance Biotherapeutics Inc |
|
972.6
|
2.5
|
L
 -2.8%
H
2.4
2.6
|
L
 -14.0%
H
2.4
2.9
|
L
 11.4%
H
2.1
3.0
|
L
 4.7%
H
1.8
3.0
|
L
 -68.0%
H
1.6
7.8
|
L
 -61.7%
H
1.6
18.3
|
L
 -94.7%
H
1.6
54.2
|
L
 -66.7%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
86.5
|
1.0
|
L
 -1%
H
1.0
1.0
|
L
 -8.3%
H
0.9
1.1
|
L
 86.8%
H
0.5
1.1
|
L
 94.1%
H
0.4
1.1
|
L
 -10.8%
H
0.3
1.2
|
L
 -80.1%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,968.3
|
78.6
|
L
 -0.6%
H
76.8
79.0
|
L
 -2.1%
H
76.2
80.8
|
L
 -16.2%
H
71.4
99.5
|
L
 16.0%
H
67.2
99.5
|
L
 25.0%
H
30.8
99.5
|
L
 332.0%
H
17.2
99.5
|
L
 -30.5%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
746.7
|
4.6
|
L
 7.5%
H
4.5
5.0
|
L
 43.4%
H
3.1
5.8
|
L
 23.1%
H
3.1
5.8
|
L
 196.1%
H
1.4
5.8
|
L
 1.8%
H
0.5
5.8
|
L
 -62.7%
H
0.5
15.7
|
L
 -58.9%
H
0.5
15.7
|
L
 -50.5%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
18.7
|
0.4
|
L
 9.4%
H
0.3
0.4
|
L
 16.7%
H
0.3
0.4
|
L
 -20.5%
H
0.3
0.6
|
L
 -47.8%
H
0.3
0.8
|
L
 -81.6%
H
0.3
2.1
|
L
 -62.4%
H
0.3
3.0
|
L
 -97.7%
H
0.3
44.9
|
L
H
0.3
195
|
| Invivyd Inc |
|
706.5
|
2.6
|
L
 2%
H
2.4
2.6
|
L
 -5.2%
H
2.4
2.7
|
L
 14.9%
H
2.2
3.0
|
L
 119.8%
H
1.3
3.1
|
L
 420.4%
H
0.4
3.1
|
L
 58.4%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
503.7
|
4.4
|
L
 2.3%
H
4.1
4.4
|
L
 0.7%
H
3.9
4.4
|
L
 9.5%
H
3.9
4.7
|
L
 1.2%
H
3.6
6.8
|
L
 364.9%
H
0.6
6.8
|
L
 -21.3%
H
0.6
7.7
|
L
 -90.3%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,654.9
|
32.8
|
L
 -3.1%
H
32.7
34.4
|
L
 -9.4%
H
32.7
36.6
|
L
 -18.6%
H
32.7
40.7
|
L
 -4.3%
H
30.5
40.7
|
L
 10.0%
H
23.2
40.7
|
L
 -39.8%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
426.9
|
2.9
|
L
 -1.7%
H
2.8
2.9
|
L
 -7.4%
H
2.8
3.1
|
L
 62.9%
H
1.8
3.5
|
L
 55.9%
H
1.7
3.5
|
L
 33.0%
H
1.3
3.5
|
L
 53.4%
H
1.3
3.9
|
L
 -5.8%
H
1.3
5.4
|
L
 -26.2%
H
0.5
8.0
|
| Immuron Ltd (ADR) |
|
6.6
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 -6.8%
H
0.7
0.9
|
L
 -47.4%
H
0.7
1.5
|
L
 -61.9%
H
0.7
2.4
|
L
 -57.1%
H
0.7
2.5
|
L
 -62.0%
H
0.7
6.0
|
L
 -87.6%
H
0.7
9.2
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
163.2
|
1.8
|
L
 -2.8%
H
1.8
1.8
|
L
 1.1%
H
1.7
1.9
|
L
 -7.3%
H
1.6
2.0
|
L
 -14.1%
H
1.6
2.4
|
L
 -5.4%
H
1.6
2.6
|
L
 -45.7%
H
1.3
4.0
|
L
 -58.9%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Inventiva (ADR) |
|
878.7
|
4.6
|
L
 -3.4%
H
4.6
4.8
|
L
 2.7%
H
4.6
4.9
|
L
 10.1%
H
4.1
4.9
|
L
 -29.6%
H
3.6
8.0
|
L
 113.0%
H
2.1
8.0
|
L
 -9.8%
H
1.5
8.0
|
L
 -68.1%
H
1.5
19.1
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
4.3
|
1.0
|
L
 3%
H
1.0
1.0
|
L
 -5.5%
H
0.9
1.1
|
L
 -6.4%
H
0.9
1.5
|
L
 -53.0%
H
0.9
2.4
|
L
 -10.4%
H
0.4
15.5
|
L
 -99.8%
H
0.4
549
|
L
 -100.0%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
| Janux Therapeutics Inc |
|
827.0
|
13.8
|
L
 0.7%
H
13.3
13.8
|
L
 -3.5%
H
13.3
14.2
|
L
 -16.2%
H
13.3
17.1
|
L
 -42.7%
H
13.3
35.3
|
L
 -74.5%
H
13.3
61.6
|
L
 -0.4%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
10,596.8
|
174.4
|
L
 0.7%
H
171.1
175.8
|
L
 2.3%
H
169.3
175.8
|
L
 4.5%
H
161
175.8
|
L
 25.0%
H
128.8
183.0
|
L
 44.1%
H
95.5
183.0
|
L
 8.7%
H
95.5
183.0
|
L
 8.7%
H
95.5
189
|
L
 27.1%
H
86.9
189
|
| Jasper Therapeutics Inc |
|
51.2
|
1.8
|
L
 -0.5%
H
1.8
1.9
|
L
 4.0%
H
1.7
1.9
|
L
 -1.6%
H
1.6
2.0
|
L
 -26.5%
H
1.4
2.7
|
L
 -90.5%
H
1.4
21.3
|
L
 -14.5%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
14.4
|
0.6
|
L
H
0.6
0.7
|
L
 -4.6%
H
0.5
0.7
|
L
 -35.4%
H
0.5
1.0
|
L
 -59.7%
H
0.5
1.9
|
L
 -92.2%
H
0.5
20.6
|
L
 -98.5%
H
0.5
49.7
|
L
 -99.8%
H
0.5
498.5
|
L
H
0.5
1337.5
|
| KalVista Pharma Inc |
|
791.6
|
15.7
|
L
 1.3%
H
15.1
15.7
|
L
 3.2%
H
14.8
16.5
|
L
 -4.5%
H
14.7
17.3
|
L
 32.2%
H
10.4
17.3
|
L
 73.4%
H
7.3
17.3
|
L
 131.0%
H
6.2
17.3
|
L
 -13.4%
H
4.1
45
|
L
 -66.4%
H
4.1
47.2
|
| Kamada Ltd |
|
417.6
|
7.2
|
L
 3.0%
H
7.2
7.3
|
L
 2.4%
H
6.9
7.3
|
L
 1.8%
H
6.6
7.5
|
L
 6.2%
H
6.5
7.5
|
L
 12.3%
H
5.5
9.2
|
L
 68.0%
H
4.1
9.2
|
L
 11.7%
H
3.7
9.2
|
L
 71.6%
H
3.3
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,112.2
|
41.1
|
L
 -2.2%
H
39.2
41.9
|
L
 -2.2%
H
39.2
42.9
|
L
 0.2%
H
39.2
44.4
|
L
 6.7%
H
35.2
44.4
|
L
 102.2%
H
17.8
44.4
|
L
 174.3%
H
10.3
44.4
|
L
 140.5%
H
7.4
44.4
|
L
H
5.0
44.4
|
| Kodiak Sciences Inc |
|
1,526.2
|
25
|
L
 -3.9%
H
23.9
26.2
|
L
 -16.4%
H
23.9
30.0
|
L
 1.0%
H
21.5
31.2
|
L
 66%
H
10.9
31.2
|
L
 174.1%
H
1.9
31.2
|
L
 194.1%
H
1.4
31.2
|
L
 -81.8%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
7.7
|
2.1
|
L
 4.0%
H
2.0
2.1
|
L
 6.6%
H
1.9
2.1
|
L
 -2.3%
H
1.9
2.2
|
L
 -23.6%
H
1.8
3.0
|
L
 -41.2%
H
1.8
4.2
|
L
 -47.5%
H
0.4
8.5
|
L
 -99.0%
H
0.4
314
|
L
 -99.9%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
126.2
|
7.4
|
L
 2.9%
H
7.1
7.4
|
L
 -0.5%
H
7.0
7.5
|
L
 25.2%
H
5.7
7.7
|
L
 16.0%
H
4.5
7.7
|
L
 -36.8%
H
0.6
12.5
|
L
 -85.4%
H
0.6
73.1
|
L
 -97.1%
H
0.6
270
|
L
 -96.3%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
546.0
|
17.9
|
L
 -3.3%
H
17.8
18.7
|
L
 -14.8%
H
17.8
21.1
|
L
 -11.6%
H
17.8
22.6
|
L
 12.4%
H
13.6
22.6
|
L
 11.3%
H
9.1
22.6
|
L
 -60.6%
H
9.1
73
|
L
 -74.2%
H
9.1
76.0
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
7,096.0
|
244.7
|
L
 -0.9%
H
235.6
247
|
L
 -3.0%
H
235.6
265.9
|
L
 10.3%
H
220.8
265.9
|
L
 33.5%
H
179.2
265.9
|
L
 54.6%
H
122.8
265.9
|
L
 206.1%
H
69.8
265.9
|
L
 311.8%
H
38.9
265.9
|
L
H
8.0
265.9
|
| TuHURA Biosciences Inc |
|
41.8
|
0.7
|
L
 -1.3%
H
0.7
0.8
|
L
 -7.5%
H
0.7
0.8
|
L
 -62.6%
H
0.7
2.0
|
L
 -71.5%
H
0.7
2.7
|
L
 -83.5%
H
0.7
5.5
|
L
 -99.7%
H
0.2
304.5
|
L
 -100.0%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
25.6
|
1.1
|
L
 -6.7%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.3
|
L
 -4.3%
H
1.0
1.3
|
L
 40.5%
H
0.3
2.1
|
L
 -64.4%
H
0.3
3.9
|
L
 63.2%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
830.1
|
9.5
|
L
 -7.7%
H
9.4
10.4
|
L
 -10.3%
H
9.4
10.6
|
L
 -20.4%
H
9.4
12.3
|
L
 -0.3%
H
8.8
12.5
|
L
 9.3%
H
5.4
12.5
|
L
 -21.3%
H
5.4
24.2
|
L
 -71.9%
H
5.4
40.0
|
L
 10.9%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
5,792.7
|
72.4
|
L
 -0.5%
H
70.4
73.5
|
L
 -11.0%
H
70.4
81.9
|
L
 9.3%
H
64.8
103
|
L
 25.1%
H
55.3
103
|
L
 77.2%
H
19.4
103
|
L
 180.9%
H
9.6
103
|
L
 17.5%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
45.9
|
6.3
|
L
 -0.3%
H
6.2
6.3
|
L
 -1.1%
H
6.2
6.4
|
L
 0.3%
H
6.2
6.4
|
L
 60.0%
H
3.5
6.4
|
L
 -8.6%
H
3.5
6.9
|
L
 -91.3%
H
0.7
74.4
|
L
 -88.1%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics Ltd (ADR) |
|
64.8
|
5.7
|
L
 14.4%
H
5.5
6.2
|
L
 -24.4%
H
5
7.5
|
L
 -57.3%
H
5
17.4
|
L
 -12.8%
H
5
17.4
|
L
 -36.4%
H
2.9
17.4
|
L
 -84.3%
H
2.9
84
|
L
 -98.7%
H
2.9
744.5
|
L
 -98.6%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
17.7
|
0.7
|
L
 9.2%
H
0.6
0.7
|
L
 34.0%
H
0.5
0.7
|
L
 -36.6%
H
0.5
1.4
|
L
 -19.3%
H
0.5
1.4
|
L
 -69.3%
H
0.5
2.4
|
L
 -73.7%
H
0.5
6.9
|
L
 -91.2%
H
0.5
12.5
|
L
 -84.4%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
292.2
|
7.8
|
L
 0.8%
H
7.7
8.0
|
L
 -6.0%
H
7.5
8.4
|
L
 0.4%
H
7.3
8.8
|
L
 11.8%
H
6.3
8.8
|
L
 11.1%
H
4.8
8.9
|
L
 22.3%
H
1.5
11.5
|
L
 -29.7%
H
1.5
12.9
|
L
 -33.0%
H
1.5
15.6
|
| Lifevantage Corp |
|
77.4
|
6.1
|
L
 1%
H
6
6.3
|
L
 0.3%
H
6
6.4
|
L
 -12.6%
H
5.7
7.0
|
L
 -35.8%
H
5.7
9.6
|
L
 -65.5%
H
5.7
27.4
|
L
 59.4%
H
3.0
27.4
|
L
 -35.4%
H
3.0
27.4
|
L
 -35.1%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
3,779.5
|
192.0
|
L
 1.0%
H
187.1
193
|
L
 -1.9%
H
186.5
196.0
|
L
 1.9%
H
179.7
203.0
|
L
 6.1%
H
177.4
212.5
|
L
 73.7%
H
93.6
212.5
|
L
 192.4%
H
49.3
212.5
|
L
 194.4%
H
46.8
212.5
|
L
 190.4%
H
36.9
212.5
|
| Longeveron Inc (Class A) |
|
12.2
|
0.6
|
L
 -3.4%
H
0.6
0.6
|
L
 7.6%
H
0.5
0.6
|
L
 -9.5%
H
0.5
0.7
|
L
 -27.9%
H
0.5
1.0
|
L
 -70.2%
H
0.5
2.2
|
L
 -98.3%
H
0.5
45.8
|
L
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
73.5
|
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
 1.4%
H
0.7
0.9
|
L
 -9.6%
H
0.7
0.9
|
L
 -3.9%
H
0.6
1.1
|
L
 -81.2%
H
0.6
7.3
|
L
 -69.0%
H
0.6
7.3
|
L
 -81.1%
H
0.6
13.1
|
L
 -99.4%
H
0.6
132.7
|
| Lixte biotech Holdings Inc |
|
32.9
|
3.8
|
L
 -1.6%
H
3.7
4.0
|
L
 -7.1%
H
3.7
4.1
|
L
 -11.1%
H
3.5
4.5
|
L
 -29.0%
H
3.5
5.2
|
L
 62.2%
H
0.6
6.3
|
L
 -34.3%
H
0.6
27
|
L
 -88.2%
H
0.6
71.9
|
L
 -86%
H
0.6
110.4
|
| Lipocine Inc |
|
40.5
|
7.3
|
L
 -8.8%
H
6.9
8.0
|
L
 39.6%
H
5.2
8.4
|
L
 135.5%
H
3.1
8.4
|
L
 117.9%
H
2.5
8.4
|
L
 44.3%
H
2.5
8.4
|
L
 -4.3%
H
2.3
11.8
|
L
 -70.0%
H
2.3
41.1
|
L
 -96.6%
H
2.3
220.8
|
| Leap Therapeutics Inc |
|
64.6
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -5%
H
1.0
1.3
|
L
 -10.2%
H
0.9
1.7
|
L
 115.1%
H
0.4
3.7
|
L
 -66.0%
H
0.2
3.7
|
L
 -75.8%
H
0.2
10.2
|
L
 -94.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
2,796.9
|
32.2
|
L
 2.4%
H
30.3
32.6
|
L
 -6.6%
H
30.3
35.2
|
L
 -5.2%
H
30.3
36.4
|
L
 43.3%
H
21.9
36.4
|
L
 161.6%
H
11.3
36.4
|
L
 430.5%
H
5.7
36.4
|
L
 971.7%
H
2.3
36.4
|
L
H
2.3
38.5
|
| Larimar Therapeutics Inc |
|
279.2
|
3.4
|
L
 -3.2%
H
3.3
3.5
|
L
 -14.5%
H
3.3
4
|
L
 -8.7%
H
3.3
4.2
|
L
 -31.0%
H
3.1
5
|
L
 -19.6%
H
1.6
5.4
|
L
 -24.7%
H
1.6
13.7
|
L
 -84.7%
H
1.5
24.0
|
L
 -95.6%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
17.0
|
1.9
|
L
 -1.5%
H
1.9
2.0
|
L
 -2.0%
H
1.8
2.0
|
L
 -4.9%
H
1.8
2.2
|
L
 -23.4%
H
1.8
3.0
|
L
 -48.5%
H
1.8
4.2
|
L
 -30.3%
H
1.8
4.5
|
L
 -91.1%
H
1.8
73.4
|
L
 -98.8%
H
1.8
199.5
|
| Lantern Pharma Inc |
|
36.3
|
3.3
|
L
 4.5%
H
3.1
3.3
|
L
 -6.6%
H
2.9
3.5
|
L
 -13.8%
H
2.9
4
|
L
 -20.9%
H
2.9
4.7
|
L
 -13.1%
H
2.6
6.1
|
L
 -47.6%
H
2.4
12.0
|
L
 -82.8%
H
2.4
23.5
|
L
H
2.4
24.8
|
| Lexicon Pharma Inc |
|
414.3
|
1.1
|
L
H
1.1
1.2
|
L
 -7.3%
H
1.1
1.2
|
L
 -19.7%
H
1.1
1.5
|
L
 -19.2%
H
1.1
1.7
|
L
 44.3%
H
0.3
1.7
|
L
 -44.4%
H
0.3
3.8
|
L
 -67.6%
H
0.3
9.7
|
L
 -91.3%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
595.0
|
28.0
|
L
 -3.4%
H
25.8
29.2
|
L
 -20.2%
H
25.8
37
|
L
 10.0%
H
24.9
45
|
L
 57.8%
H
15.7
45
|
L
 100.6%
H
7.7
45
|
L
 -60.9%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Lyra Therapeutics Inc |
|
6.0
|
3.4
|
L
 7.0%
H
3.1
3.4
|
L
 -5.9%
H
3.0
3.6
|
L
 -24.9%
H
3.0
4.6
|
L
 -51.7%
H
2.8
8.8
|
L
 -67.5%
H
2.8
37.5
|
L
 -97.8%
H
2.8
339.5
|
L
 -99.4%
H
2.8
825
|
L
H
2.8
1100
|
| Legend Biotech Corp (ADR) |
|
3,751.0
|
20.3
|
L
 -5.6%
H
20.3
21.7
|
L
 -9.9%
H
20.3
22.3
|
L
 -27.0%
H
20.3
29.0
|
L
 -36.7%
H
20.3
34.8
|
L
 -43.2%
H
20.3
45.3
|
L
 -59.1%
H
20.3
77.3
|
L
 -27.4%
H
20.3
77.3
|
L
H
20.3
77.3
|
| Mustang Bio Inc |
|
8.1
|
1.1
|
L
 3.7%
H
1.0
1.2
|
L
 8.8%
H
0.9
1.2
|
L
 -15.9%
H
0.9
1.3
|
L
 -29.8%
H
0.9
1.9
|
L
 -89.8%
H
0.1
13.3
|
L
 -99.7%
H
0.1
554.2
|
L
 -100.0%
H
0.1
3915
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
140.4
|
2.1
|
L
 -1.0%
H
2.1
2.1
|
L
 -2.8%
H
2.0
2.1
|
L
 -15.0%
H
2.0
2.6
|
L
 -31.9%
H
1.7
3.5
|
L
 -2.3%
H
1.3
4.7
|
L
 -40.1%
H
0.8
4.7
|
L
 -70.8%
H
0.8
10.7
|
L
 -99.7%
H
0.8
729
|
| Moleculin Biotech Inc |
|
8.1
|
3.9
|
L
 7.7%
H
3.6
4.1
|
L
 1.8%
H
3.1
4.1
|
L
 -49.4%
H
3.1
8.0
|
L
 -66.2%
H
3.1
15.8
|
L
 -91.3%
H
3.1
91.3
|
L
 -99.1%
H
3.1
3318.8
|
L
 -99.8%
H
3.1
3318.8
|
L
H
3.1
21555
|
| Seres Therapeutics Inc |
|
137.4
|
15.2
|
L
 0.3%
H
14.5
15.4
|
L
 3.7%
H
14.0
15.4
|
L
 -15.1%
H
14.0
17.9
|
L
 -26.2%
H
12.5
30.0
|
L
 1587.8%
H
0.4
30.0
|
L
 177.7%
H
0.4
30.0
|
L
 -39.4%
H
0.4
30.0
|
L
 -55.5%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
13,363.4
|
588.4
|
L
 -0.9%
H
572.5
593.0
|
L
 -1.8%
H
572.5
600.0
|
L
 0.4%
H
535.3
615
|
L
 32.8%
H
393.6
615
|
L
 84.1%
H
265
615
|
L
 114.4%
H
119.8
615
|
L
 436.1%
H
52.3
615
|
L
 4994.4%
H
5.3
615
|
| MediWound Ltd |
|
236.9
|
18.5
|
L
 0.3%
H
18.2
18.8
|
L
 -1.7%
H
18.2
19
|
L
 2.8%
H
17.6
19.6
|
L
 7.5%
H
16.7
20.0
|
L
 3.6%
H
14.1
22.5
|
L
 41.4%
H
7.1
24
|
L
 -30.0%
H
7.1
43.5
|
L
 -68.8%
H
7.1
65.0
|
| MEI Pharma Inc |
|
56.3
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 13.3%
H
1.3
1.6
|
L
 -12.6%
H
1.3
1.9
|
L
 -40.2%
H
1.3
3.0
|
L
 -42.9%
H
1.3
9
|
L
 -73.6%
H
1.3
9
|
L
 -97.2%
H
1.3
91.5
|
L
 -95.4%
H
1.3
102.8
|
| Macrogenics Inc |
|
108.8
|
1.7
|
L
 6.8%
H
1.6
1.8
|
L
 6.8%
H
1.5
1.8
|
L
 24.6%
H
1.3
1.8
|
L
 -3.4%
H
1.3
2.2
|
L
 -49.1%
H
1.0
3.6
|
L
 -72.0%
H
1.0
21.9
|
L
 -92.3%
H
1.0
36.5
|
L
 -94.2%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
12.8
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 16.9%
H
0.7
0.9
|
L
 -29.7%
H
0.5
1.4
|
L
 -63.4%
H
0.5
2.8
|
L
 -66.5%
H
0.5
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
36.9
|
L
 -7.0%
H
36.2
40.8
|
L
 -11.8%
H
36.2
42.9
|
L
 -17.5%
H
36.2
45.1
|
L
 5.6%
H
32.2
45.5
|
L
 87.4%
H
16.6
45.5
|
L
 424.0%
H
5.9
45.5
|
L
 -69.9%
H
5.1
227.2
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
607.7
|
7.6
|
L
 -3.3%
H
7.4
7.9
|
L
 -5.3%
H
7.4
8.3
|
L
 -12.2%
H
7.4
9.5
|
L
 -10.7%
H
7.3
9.7
|
L
 17.6%
H
4.6
9.7
|
L
 13.4%
H
3.5
9.7
|
L
 -51.4%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
3,905.2
|
75.6
|
L
 -3.2%
H
73.8
77.5
|
L
 -4.7%
H
73.8
80.5
|
L
 5.6%
H
63.2
82.6
|
L
 3.6%
H
63.2
82.6
|
L
 76.5%
H
36.9
82.6
|
L
 285.7%
H
18.5
82.6
|
L
 316.3%
H
12.8
82.6
|
L
H
6.5
82.6
|
| Milestone Pharma Inc |
|
172.0
|
2.0
|
L
 -1.5%
H
2.0
2.1
|
L
 -2.9%
H
2.0
2.1
|
L
 -23.5%
H
1.6
3.1
|
L
 -4.3%
H
1.6
3.1
|
L
 -6.5%
H
0.6
3.1
|
L
 -50.7%
H
0.6
4.5
|
L
 -70.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
792.8
|
11.2
|
L
 -6.4%
H
11.1
12.0
|
L
 -19.1%
H
11.1
13.9
|
L
 -25.4%
H
11.1
15.6
|
L
 32.7%
H
8.2
15.6
|
L
 -79.1%
H
6.0
62.8
|
L
 -6.3%
H
6.0
65.0
|
L
 3.2%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,822.1
|
35.7
|
L
 -0.1%
H
34.2
35.8
|
L
 -4.0%
H
34.2
37.6
|
L
 -8.4%
H
34.2
39.7
|
L
 -6.3%
H
33.6
47.7
|
L
 180.6%
H
8.2
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,725.7
|
5.6
|
L
 0.4%
H
5.5
5.6
|
L
 -2.9%
H
5.5
5.8
|
L
 -1.6%
H
5.5
6.1
|
L
 -2.4%
H
4.8
6.2
|
L
 -13.3%
H
3.4
6.6
|
L
 8.1%
H
3.2
7.6
|
L
 74.5%
H
2.5
7.6
|
L
 -22.5%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,320.2
|
13.6
|
L
 -0.4%
H
13.3
14.8
|
L
 4.0%
H
12.9
14.8
|
L
 9.3%
H
12
14.8
|
L
 8.1%
H
10.5
14.8
|
L
 87.3%
H
4.7
14.8
|
L
 420.3%
H
2.4
14.8
|
L
 -68.9%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
67.8
|
1.4
|
L
 3.8%
H
1.3
1.4
|
L
 8.7%
H
1.3
1.4
|
L
 -11.0%
H
1.2
1.6
|
L
 7.8%
H
1.2
2.0
|
L
 -35.2%
H
1.1
2.2
|
L
 -38.9%
H
1.1
2.7
|
L
 -73.8%
H
1.1
10.8
|
L
 -61.9%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
412.5
|
61.7
|
L
 -6.5%
H
60.3
66.5
|
L
 -10.2%
H
60.3
70.4
|
L
 -22.3%
H
60.3
85.0
|
L
 -37.9%
H
60.3
105
|
L
 168.6%
H
22.5
105
|
L
 407.2%
H
1.4
105
|
L
 94.1%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
29.8
|
1.8
|
L
 16.2%
H
1.6
1.8
|
L
 24.3%
H
1.4
1.8
|
L
 26.1%
H
1.3
1.8
|
L
 86.5%
H
0.8
1.8
|
L
 -45.6%
H
0.8
4.1
|
L
 -41.3%
H
0.7
9.7
|
L
 -87.8%
H
0.7
37.7
|
L
 -97.5%
H
0.7
135.5
|
| Moderna |
|
12,569.9
|
32.2
|
L
 4.2%
H
31.3
32.5
|
L
 3.1%
H
29.1
32.5
|
L
 26.2%
H
25.4
35.9
|
L
 12.9%
H
22.3
35.9
|
L
 -22.7%
H
22.3
48.1
|
L
 -81.9%
H
22.3
207.5
|
L
 -71.2%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Mersana Therapeutics Inc |
|
145.4
|
29.1
|
L
 0.1%
H
28.8
30.4
|
L
H
28.1
30.4
|
L
 5.9%
H
27.4
30.4
|
L
 251.2%
H
7.5
30.4
|
L
 -16.3%
H
5.2
36.3
|
L
 -78.5%
H
5.2
240.5
|
L
 -95.6%
H
5.2
678.3
|
L
H
5.2
727.3
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
549.6
|
3.8
|
L
 11.5%
H
3.4
3.8
|
L
 15.9%
H
3.2
3.8
|
L
 2.4%
H
3.2
4.0
|
L
 22.7%
H
2.5
4.0
|
L
 -30.6%
H
1.7
6.2
|
L
 -72.9%
H
1.7
16.9
|
L
 -86.2%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
15.0
|
7.9
|
L
 -5.8%
H
7.8
8.3
|
L
 2.7%
H
7.3
9.4
|
L
 -15.4%
H
6.9
9.6
|
L
 -11.8%
H
6.9
12.5
|
L
 -46.6%
H
6.9
16.5
|
L
 -54.4%
H
6.8
21.2
|
L
 -57.9%
H
6.8
49.1
|
L
 -58.5%
H
6.5
49.1
|
| MaxCyte Inc |
|
165.3
|
1.6
|
L
H
1.5
1.6
|
L
 -3.7%
H
1.5
1.6
|
L
 -1.9%
H
1.4
1.7
|
L
 -9.4%
H
1.4
1.9
|
L
 -64.7%
H
1.3
5.2
|
L
 -69.1%
H
1.3
6.0
|
L
 -4.9%
H
1.3
17.4
|
L
H
1.3
17.4
|
| TNF Pharma Inc |
|
18.9
|
4.5
|
L
 7.3%
H
4.1
4.7
|
L
 -4.6%
H
3.9
4.7
|
L
 -34.4%
H
3.9
8.2
|
L
 -21.0%
H
2.5
8.2
|
L
 -96.2%
H
2.5
152
|
L
 -99.9%
H
2.5
8940
|
L
 -99.9%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
11.5
|
1.3
|
L
 9.5%
H
1.2
1.3
|
L
H
1.1
1.3
|
L
 8.6%
H
1
1.4
|
L
 -26.6%
H
0.9
2.1
|
L
 -71%
H
0.9
8.2
|
L
 -99.5%
H
0.9
314
|
L
H
0.9
1200
|
L
H
0.9
1200
|
| Mesoblast Ltd (ADR) |
|
2,353.9
|
18.3
|
L
 0.7%
H
18.1
18.7
|
L
 -6.2%
H
17.9
19.1
|
L
 6.4%
H
17.5
19.9
|
L
 -0.7%
H
14.1
20.2
|
L
 -9.1%
H
9.6
21
|
L
 513.8%
H
1.0
22
|
L
 114.9%
H
1.0
22
|
L
 199.3%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
157.5
|
4.2
|
L
 -0.2%
H
4.2
4.3
|
L
 -0.5%
H
4.2
4.4
|
L
 -6.9%
H
3.9
4.6
|
L
 13.5%
H
3.5
4.8
|
L
 -13.6%
H
3.4
5.9
|
L
 -35.6%
H
3.3
12.7
|
L
 -80.2%
H
3.3
32.0
|
L
 -88.2%
H
3.3
36
|
| Mereo Biopharma Grp PLC (ADR) |
|
76.4
|
0.5
|
L
 -5.9%
H
0.5
0.6
|
L
 -79.2%
H
0.2
0.6
|
L
 -76.5%
H
0.2
2.4
|
L
 -76.5%
H
0.2
2.4
|
L
 -87.1%
H
0.2
3.8
|
L
 -35.1%
H
0.2
5.0
|
L
 -86.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
22.9
|
3.7
|
L
 3.1%
H
3.5
3.7
|
L
 8.2%
H
3.4
3.7
|
L
 7.3%
H
3.1
3.7
|
L
 31.2%
H
2.6
3.7
|
L
 -14.4%
H
2.6
4.4
|
L
 -58.7%
H
2.6
10.1
|
L
 -65.1%
H
2.6
19.9
|
L
 -64.5%
H
2.6
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,796.3
|
33.5
|
L
 -4.9%
H
32.7
35.5
|
L
 -5.1%
H
32.7
36
|
L
 -6.6%
H
32.7
37.4
|
L
 9.2%
H
31
42
|
L
 28.9%
H
14.1
42
|
L
 181.8%
H
5.6
42
|
L
H
5.6
42
|
L
H
5.6
42
|
| Nature`s Sunshine Products Inc |
|
373.7
|
21.4
|
L
 1.9%
H
20.9
21.9
|
L
 -1.2%
H
20.9
22.5
|
L
 0.9%
H
20.3
24.1
|
L
 37.7%
H
13.0
24.1
|
L
 45.8%
H
11.0
24.1
|
L
 152.2%
H
8.3
24.1
|
L
 47.6%
H
7.9
24.1
|
L
 115.1%
H
5.5
24.1
|
| Nautilus biotech Inc |
|
238.7
|
1.9
|
L
 -1.1%
H
1.9
1.9
|
L
 -4.6%
H
1.9
2.1
|
L
 -8.7%
H
1.8
2.1
|
L
 114.8%
H
0.8
2.5
|
L
 13.2%
H
0.6
2.5
|
L
 11.8%
H
0.6
4.7
|
L
 -82.6%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
13,559.0
|
136.0
|
L
 -3.3%
H
134.0
138.2
|
L
 -6.4%
H
134.0
145.5
|
L
 -11.8%
H
134.0
160.2
|
L
 -0.8%
H
133.6
160.2
|
L
 -1.7%
H
84.2
160.2
|
L
 12.5%
H
84.2
160.2
|
L
 41.8%
H
71.9
160.2
|
L
 159.8%
H
31.3
160.2
|
| Minerva Neurosciences Inc |
|
179.6
|
4.2
|
L
 5.9%
H
3.9
4.2
|
L
 -1.0%
H
3.8
4.2
|
L
 11.0%
H
3.5
4.3
|
L
 97.6%
H
2.1
12.5
|
L
 86.1%
H
1.2
12.5
|
L
 150%
H
1.2
13.5
|
L
 -78.2%
H
1.2
30
|
L
 -91.2%
H
1.2
126.7
|
| Nektar Therapeutics |
|
904.6
|
44.5
|
L
 2.4%
H
43
44.5
|
L
 0.0%
H
41.3
44.5
|
L
 -22.9%
H
41.3
59.2
|
L
 -26.6%
H
41.3
66.9
|
L
 163.8%
H
6.5
66.9
|
L
 26.7%
H
6.2
66.9
|
L
 -83.2%
H
6.2
401.3
|
L
 -81.7%
H
6.2
1670.4
|
| Nkarta Inc |
|
135.0
|
1.9
|
L
 1.6%
H
1.8
1.9
|
L
 3.3%
H
1.8
1.9
|
L
 3.3%
H
1.7
1.9
|
L
 -10.8%
H
1.7
2.7
|
L
 -24%
H
1.3
2.7
|
L
 -69.8%
H
1.3
16.2
|
L
 -96.8%
H
1.3
61.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
10.2
|
2.2
|
L
 6.7%
H
2.1
2.7
|
L
 -10.8%
H
1.9
2.7
|
L
 -38.2%
H
1.9
4.7
|
L
 -88.8%
H
1.9
19.8
|
L
 -88.6%
H
1.9
33.7
|
L
 -99.6%
H
1.2
752
|
L
H
1.2
2940
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
18.4
|
L
 -8.6%
H
18.3
20.3
|
L
 -7.9%
H
18.3
23.0
|
L
 -12.9%
H
18.3
23.0
|
L
 -17.5%
H
18.3
37.3
|
L
 2.5%
H
14.7
37.3
|
L
 80.7%
H
9.8
37.3
|
L
 -93.5%
H
7.5
317.8
|
L
 -92.5%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.4
|
L
 -1.1%
H
7.2
7.5
|
L
 1.0%
H
7.2
7.5
|
L
 -1.5%
H
7.0
7.6
|
L
 5.4%
H
6.4
7.8
|
L
 3.4%
H
6.2
7.8
|
L
 275.5%
H
0.0
7.8
|
L
 -56.1%
H
0.0
45.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
20.2
|
8.7
|
L
 -8.7%
H
8.5
9.6
|
L
 -5.0%
H
8.0
9.6
|
L
 19.3%
H
7.2
13.4
|
L
 -23.0%
H
6.1
14.9
|
L
 -62.3%
H
6.1
30.3
|
L
 -86.8%
H
6.1
83.6
|
L
 -99.9%
H
6.1
20088.8
|
L
H
6.1
1424940
|
| Nurix Therapeutics Inc |
|
1,772.9
|
17.5
|
L
 -3.2%
H
17.1
18.1
|
L
 -9.4%
H
17.1
19.5
|
L
 -2.9%
H
17.1
22.5
|
L
 86.5%
H
9
22.5
|
L
 -12.1%
H
8.2
22.5
|
L
 61.6%
H
4.2
29.6
|
L
 -46.3%
H
4.2
51.5
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
26.1
|
0.9
|
L
 12.8%
H
0.8
0.9
|
L
 10%
H
0.7
0.9
|
L
 -26.7%
H
0.7
1.2
|
L
 -29.6%
H
0.7
1.3
|
L
 -26.7%
H
0.7
2.6
|
L
 -33.3%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
71.3
|
2.4
|
L
 -8.0%
H
2.4
2.6
|
L
 -5.9%
H
2.4
2.8
|
L
 -1.2%
H
2.0
2.8
|
L
 -26.3%
H
2.0
3.8
|
L
 -10.4%
H
1.6
6.0
|
L
 -79.6%
H
1.1
54
|
L
 -99.0%
H
1.1
642
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,085.3
|
9.4
|
L
 1.7%
H
9.1
9.7
|
L
 -0.7%
H
8.9
9.7
|
L
 -3.8%
H
8.7
10.0
|
L
 -53.1%
H
8.0
28.3
|
L
 -22.8%
H
5.9
28.3
|
L
 -76.1%
H
5.9
47.5
|
L
 -83.2%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,605.7
|
97.9
|
L
 -2.9%
H
95.5
103.4
|
L
 -5.9%
H
95.5
103.5
|
L
 -8.4%
H
95.5
111.9
|
L
 16.3%
H
82
112.9
|
L
 21.2%
H
55.5
112.9
|
L
 243.4%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,178.1
|
7.3
|
L
 1.7%
H
7.1
7.4
|
L
 6.2%
H
6.6
7.4
|
L
 5.7%
H
6.4
7.4
|
L
 -23.4%
H
6.2
9.6
|
L
 -16.6%
H
5.0
11.6
|
L
 -36.0%
H
3.5
23.9
|
L
 -93.6%
H
3.5
331.7
|
L
 -95.4%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
218.5
|
8.5
|
L
 0.2%
H
8.2
8.7
|
L
 10.1%
H
7.2
8.7
|
L
 26.6%
H
6.5
8.7
|
L
 42.2%
H
5.6
8.7
|
L
 51.5%
H
5.3
11.5
|
L
 13.9%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
47.7
|
13.6
|
L
 2.4%
H
13.0
14.1
|
L
 6.5%
H
12.5
14.6
|
L
 6.8%
H
10.4
14.6
|
L
 132.9%
H
5.8
15.7
|
L
 36.4%
H
2.8
15.7
|
L
 -26.4%
H
2.8
30.8
|
L
 -89.6%
H
2.8
172.8
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
15.4
|
3.7
|
L
 1.7%
H
3.6
3.7
|
L
 11.8%
H
3.2
3.8
|
L
 -16.5%
H
3.2
4.6
|
L
 -20.9%
H
3.1
7.2
|
L
 -100.0%
H
2.8
54800
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
| Ocugen Inc |
|
452.9
|
1.5
|
L
 5.1%
H
1.3
1.5
|
L
 2.8%
H
1.3
1.5
|
L
 16.9%
H
1.2
1.6
|
L
 -18.1%
H
1.1
1.9
|
L
 61.1%
H
0.5
1.9
|
L
 9.0%
H
0.3
2.1
|
L
 -52.8%
H
0.3
18.8
|
L
 -99.3%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,141.7
|
19.8
|
L
 -1.3%
H
19.7
20.4
|
L
 -3.7%
H
19.6
21.0
|
L
 0.3%
H
19.1
21.9
|
L
 12.4%
H
17.9
22
|
L
 12.5%
H
14
23.1
|
L
 95.5%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
| Ocular Therapeutix Inc |
|
2,460.7
|
11.6
|
L
 -2.3%
H
11.3
12.0
|
L
 -8.0%
H
11.3
12.7
|
L
 -7.1%
H
11.3
16.4
|
L
 1.2%
H
10.3
16.4
|
L
 28.9%
H
5.8
16.4
|
L
 264.4%
H
2
16.4
|
L
 -42.0%
H
2
23.7
|
L
 29.8%
H
2
24.3
|
| Opus Genetics Inc |
|
146.9
|
2.1
|
L
 0.5%
H
1.9
2.2
|
L
 5.5%
H
1.9
2.3
|
L
 -4.5%
H
1.9
2.6
|
L
 13.3%
H
1.7
2.6
|
L
 66.4%
H
0.7
2.6
|
L
 -40.3%
H
0.7
6.6
|
L
 -69.6%
H
0.7
13.8
|
L
 -98.7%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
214.1
|
7.5
|
L
 4.3%
H
7.1
7.5
|
L
 17.3%
H
6.2
7.5
|
L
 33.9%
H
4.7
7.5
|
L
 123.0%
H
3.2
8.5
|
L
 215.2%
H
1.9
8.5
|
L
 7.5%
H
1.9
10
|
L
 -84.4%
H
1.9
131.4
|
L
 -95.9%
H
1.9
204.8
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
90.3
|
2.4
|
L
 7.6%
H
2.1
2.5
|
L
 20.6%
H
1.9
2.5
|
L
 19.4%
H
1.8
2.5
|
L
 17.1%
H
1.7
2.9
|
L
 116.2%
H
0.9
3.4
|
L
 18.8%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
2,012.0
|
25.1
|
L
 -0.7%
H
24.5
25.6
|
L
 -4.3%
H
24.5
26.2
|
L
 -9.2%
H
24.5
36.3
|
L
 126.1%
H
6.7
36.3
|
L
 332.8%
H
2.9
36.3
|
L
 884.3%
H
2.5
36.3
|
L
 -45.1%
H
2
54.9
|
L
H
2
60.3
|
| Omeros Corp |
|
1,091.9
|
15.4
|
L
 -6.0%
H
15.3
16.4
|
L
 -2.0%
H
14.4
17.6
|
L
 39.6%
H
8.3
17.7
|
L
 236.2%
H
4.1
17.7
|
L
 37.4%
H
3.0
17.7
|
L
 438.5%
H
0.9
17.7
|
L
 6.1%
H
0.9
23.9
|
L
 4.1%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
103.3
|
1.0
|
L
 -2.0%
H
0.9
1
|
L
 1.1%
H
0.9
1
|
L
 -2.0%
H
0.9
1.1
|
L
 -30.4%
H
0.9
1.4
|
L
H
0.3
1.5
|
L
 -38.9%
H
0.3
3.4
|
L
 -59.0%
H
0.3
4.8
|
L
 -65.3%
H
0.3
8.5
|
| Traws Pharma Inc |
|
10.3
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 10.3%
H
1.1
1.4
|
L
 -45.3%
H
1.1
2.6
|
L
 -42.7%
H
1.1
3.3
|
L
 -85%
H
1.0
9.5
|
L
 -92.7%
H
1.0
37.3
|
L
 -99.3%
H
1.0
723.8
|
L
 -100.0%
H
1.0
57796.9
|
| VivoSim Labs Inc |
|
5.1
|
2.0
|
L
 3.7%
H
1.9
2.0
|
L
 -3.0%
H
1.7
2.0
|
L
 -14.9%
H
1.7
2.5
|
L
 -42.7%
H
1.7
3.5
|
L
 -64.2%
H
0.3
22.0
|
L
 -88.7%
H
0.3
40.8
|
L
 -98.7%
H
0.3
287.0
|
L
 -99.7%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
793.7
|
8.2
|
L
 -0.2%
H
7.8
8.3
|
L
 -1.2%
H
7.8
8.4
|
L
 -28.5%
H
7.8
12.5
|
L
 -29.5%
H
7.8
14.9
|
L
 -4.7%
H
3.9
14.9
|
L
 41.0%
H
3.9
16.7
|
L
 -75.5%
H
2.4
39.5
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
117.8
|
3.0
|
L
 1.7%
H
2.9
3.0
|
L
 0.3%
H
2.8
3.0
|
L
 8.8%
H
2.7
3.2
|
L
 21.3%
H
2.1
3.2
|
L
 21.3%
H
1.8
3.2
|
L
 -76.7%
H
1.7
13.7
|
L
 -32.0%
H
1.7
31.5
|
L
 -65.1%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
34.6
|
0.5
|
L
 -18.2%
H
0.5
0.7
|
L
 -70.3%
H
0.5
2.0
|
L
 -73.8%
H
0.5
2.5
|
L
 -49.1%
H
0.5
2.5
|
L
 -75.9%
H
0.5
3.0
|
L
 -99.9%
H
0.5
812
|
L
 -99.9%
H
0.5
1704
|
L
H
0.5
17568
|
| Ovid Therapeutics Inc |
|
118.2
|
1.7
|
L
 -5.7%
H
1.6
1.8
|
L
 -6.7%
H
1.6
1.8
|
L
 2.5%
H
1.3
1.9
|
L
 -9.8%
H
1.2
1.9
|
L
 72.9%
H
0.2
2.0
|
L
 -12.6%
H
0.2
4.1
|
L
 -31.7%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,555.3
|
38.4
|
L
 2.9%
H
36.8
38.7
|
L
 0.5%
H
36.5
38.7
|
L
 -5.9%
H
36.1
41.6
|
L
 0.1%
H
35.8
46.4
|
L
 87.0%
H
16.2
46.4
|
L
 178.6%
H
9.4
46.4
|
L
 94.7%
H
9.4
46.4
|
L
 31.4%
H
9.4
54.6
|
| Palisade Bio Inc |
|
313.3
|
2.1
|
L
 -16%
H
2.1
2.6
|
L
 -2.3%
H
2.1
2.6
|
L
 16.7%
H
1.7
2.6
|
L
 31.3%
H
1.5
2.6
|
L
 10.5%
H
0.5
2.6
|
L
 -96.5%
H
0.4
57.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1275300
|
| Passage Bio Inc |
|
51.2
|
16.1
|
L
 37.8%
H
13.3
16.7
|
L
 48.3%
H
9.6
16.7
|
L
 75.5%
H
8.2
16.7
|
L
 102.6%
H
6.2
16.7
|
L
 -2.8%
H
5.1
16.7
|
L
 -54.7%
H
5.1
38.4
|
L
 -97.1%
H
5.1
617.4
|
L
H
5.1
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.5
|
2.2
|
L
 8.4%
H
2.0
2.5
|
L
 0.9%
H
1.6
2.5
|
L
 -31.6%
H
1.4
6.6
|
L
 -97.9%
H
1.4
124
|
L
 -98.3%
H
1.4
150
|
L
 -99.5%
H
1.4
670
|
L
 -99.9%
H
1.4
5160
|
L
H
1.4
12200
|
| Puma biotech Inc |
|
299.3
|
5.9
|
L
 3.0%
H
5.7
6
|
L
 -3.6%
H
5.6
6.3
|
L
 12.3%
H
5.2
6.3
|
L
 15.8%
H
4.6
6.3
|
L
 101.4%
H
2.6
6.3
|
L
 41.4%
H
2.1
7.7
|
L
 -42.5%
H
1.6
14.1
|
L
 -91.9%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,079.8
|
25.1
|
L
 2.6%
H
24.2
25.6
|
L
 -5.3%
H
24.2
26.8
|
L
 4.7%
H
23.6
27.2
|
L
 1.1%
H
19.8
27.2
|
L
 33.7%
H
18.2
27.6
|
L
 -35.1%
H
11.2
48.6
|
L
 -57.7%
H
11.2
82.2
|
L
 -66.8%
H
11.2
82.2
|
| Processa Pharma Inc |
|
7.3
|
3.2
|
L
 10.2%
H
3
3.4
|
L
 -17.6%
H
2.8
3.9
|
L
 -52.4%
H
2.8
8.9
|
L
 -39.3%
H
2.8
14.3
|
L
 -86.8%
H
2.8
27
|
L
 -99.4%
H
2.8
725
|
L
 -99.9%
H
2.8
7120
|
L
 -100.0%
H
2.8
17937.5
|
| Vaxcyte Inc |
|
6,025.6
|
46.0
|
L
 -0.9%
H
43.9
46.6
|
L
 -2%
H
43.9
47.8
|
L
 -0.1%
H
42.4
48.7
|
L
 7.9%
H
39.9
50.3
|
L
 -45.8%
H
27.7
93.8
|
L
 -1.8%
H
27.7
121.1
|
L
 70.4%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
46.5
|
0.9
|
L
 2.4%
H
0.8
0.9
|
L
 -5.6%
H
0.8
0.9
|
L
 -4.5%
H
0.8
1.1
|
L
 -16.7%
H
0.7
1.2
|
L
 -51.7%
H
0.7
2.2
|
L
 -92.9%
H
0.7
12.2
|
L
 -62.7%
H
0.7
17.9
|
L
 -99.7%
H
0.6
355.4
|
| PepGen Inc |
|
458.6
|
6.7
|
L
 -7.0%
H
6.5
7.3
|
L
 14.8%
H
5.7
7.8
|
L
 25.6%
H
5.0
7.8
|
L
 30.0%
H
4.1
7.8
|
L
 74.2%
H
0.9
7.8
|
L
 -54.6%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,479.0
|
4.2
|
L
 -2.3%
H
4.0
4.4
|
L
 0.5%
H
4.0
4.5
|
L
 11.5%
H
3.4
4.5
|
L
 28.6%
H
3.0
5.2
|
L
 294.3%
H
1.1
5.2
|
L
 167.9%
H
0.7
5.2
|
L
 -61.8%
H
0.7
10.8
|
L
 -85.7%
H
0.7
40.2
|
| Phathom Pharma Inc |
|
1,126.1
|
15.8
|
L
 0.8%
H
15.4
16.0
|
L
 -9.9%
H
15.4
17.7
|
L
 7.7%
H
14.1
18.3
|
L
 29.7%
H
10.3
18.3
|
L
 104.5%
H
2.2
18.3
|
L
 91.6%
H
2.2
19.7
|
L
 -53.2%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
12.6
|
1.2
|
L
 7.3%
H
1.1
1.2
|
L
 8.3%
H
1.0
1.2
|
L
 -13.3%
H
1
1.4
|
L
 -51.1%
H
1
4.2
|
L
 -40.6%
H
1.0
9.8
|
L
 -97.3%
H
0.6
110.4
|
L
 -99.6%
H
0.6
470.9
|
L
 -100.0%
H
0.6
237421.8
|
| Pharvaris NV |
|
1,616.2
|
24.9
|
L
 -6.0%
H
23.6
26.6
|
L
 -3.4%
H
23.6
28.4
|
L
 -10.2%
H
23.2
28.4
|
L
 6.4%
H
20.7
29.8
|
L
 35.1%
H
11.5
29.8
|
L
 102.8%
H
6.0
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
78.7
|
1.3
|
L
 2.4%
H
1.2
1.3
|
L
 5.8%
H
1.2
1.3
|
L
 -2.3%
H
1.2
1.4
|
L
 -15.8%
H
1.2
2.0
|
L
 -90.5%
H
1.1
13.7
|
L
 -93.2%
H
1.1
36.6
|
L
 -94.8%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
27.4
|
3.0
|
L
 -1%
H
2.9
3.0
|
L
 -4.8%
H
2.9
3.2
|
L
 -9.2%
H
2.8
3.9
|
L
 -35.8%
H
2.8
4.9
|
L
 -31.6%
H
2.8
7.1
|
L
 -64.1%
H
0.7
11.6
|
L
 -94.8%
H
0.7
79.1
|
L
 -96.7%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
7.7
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 7.0%
H
0.7
0.8
|
L
 -37.2%
H
0.7
1.5
|
L
 -26.9%
H
0.6
1.5
|
L
 -53.7%
H
0.6
1.9
|
L
 -74.7%
H
0.6
3.2
|
L
 -93.2%
H
0.6
55.5
|
L
 -99.1%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
6,925.0
|
276.9
|
L
 -3.3%
H
272.1
288.1
|
L
 3.0%
H
272.1
317.7
|
L
 45.8%
H
240.4
317.7
|
L
 409.2%
H
50.3
317.7
|
L
 245.5%
H
26.7
317.7
|
L
 607.3%
H
11.9
317.7
|
L
 -65.9%
H
11.9
914.3
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
2.7
|
0.7
|
L
 -2.9%
H
0.7
0.7
|
L
 -18.1%
H
0.6
0.8
|
L
 -33.3%
H
0.6
1.2
|
L
 -50.7%
H
0.6
1.5
|
L
 -79.9%
H
0.6
6.7
|
L
 -97.4%
H
0.2
158.5
|
L
 -99.7%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
153.4
|
2.4
|
L
 -10.6%
H
2.4
2.8
|
L
 -0.4%
H
2.4
3
|
L
 58.4%
H
1.4
3
|
L
 66.0%
H
1.2
4.2
|
L
 82.1%
H
0.6
4.2
|
L
 -50.6%
H
0.6
8.6
|
L
 -96.4%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
644.4
|
3.6
|
L
 1.1%
H
3.4
3.7
|
L
 2%
H
3.3
3.7
|
L
 -7.3%
H
3.3
4.4
|
L
 -43.5%
H
3.2
6.9
|
L
 14.8%
H
1.1
6.9
|
L
 -79.3%
H
1.1
21.5
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
302.9
|
2.1
|
L
 -4.0%
H
2.1
2.2
|
L
 -15.4%
H
2.1
2.6
|
L
 -16.7%
H
2.1
2.7
|
L
 -21.9%
H
2.0
3.5
|
L
 15.1%
H
0.5
7.1
|
L
 -69.0%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
214.9
|
2.0
|
L
 2.5%
H
1.9
2.1
|
L
 -6.0%
H
1.9
2.3
|
L
 -3.8%
H
1.9
2.5
|
L
 -16.7%
H
1.9
3.1
|
L
 -26.1%
H
1.1
3.1
|
L
 -39.3%
H
1.1
4.6
|
L
 -50.7%
H
0.5
9.5
|
L
 -73.6%
H
0.5
24
|
| Prothena Corporation plc |
|
489.9
|
9.1
|
L
 -1.1%
H
8.9
9.2
|
L
 -4.6%
H
8.9
9.7
|
L
 -18.5%
H
8.9
11.5
|
L
 -8.3%
H
8.9
11.7
|
L
 -34.4%
H
4.3
16.7
|
L
 -83.0%
H
4.3
79.7
|
L
 -26.0%
H
4.3
79.8
|
L
 -85.4%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
6.5
|
0.8
|
L
 5.3%
H
0.7
0.8
|
L
 21.2%
H
0.6
0.9
|
L
 -53.2%
H
0.6
1.9
|
L
 -86.1%
H
0.6
13.8
|
L
 -83.9%
H
0.6
15.8
|
L
 -99.4%
H
0.6
153.4
|
L
 -99.8%
H
0.6
899.5
|
L
 -99.7%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
77.0
|
0.6
|
L
H
0.5
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -15.2%
H
0.5
0.8
|
L
 -23.3%
H
0.5
0.9
|
L
 -54.5%
H
0.2
2.3
|
L
 -88.7%
H
0.2
7.2
|
L
 -98.2%
H
0.2
81.3
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
6,162.9
|
76.8
|
L
 0.0%
H
74.2
76.8
|
L
 -2.3%
H
74.2
78.7
|
L
 -1.4%
H
73.1
80.2
|
L
 17.4%
H
62.3
87.5
|
L
 64.9%
H
36.0
87.5
|
L
 94.3%
H
17.5
87.5
|
L
 26.9%
H
17.5
87.5
|
L
 148.7%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
5,262.6
|
84.2
|
L
 -3.4%
H
82.9
87.5
|
L
 -5.2%
H
82.9
89.1
|
L
 -3.6%
H
82.9
96.5
|
L
 29.9%
H
62.2
96.5
|
L
 112.7%
H
33.7
96.5
|
L
 659.1%
H
10.9
96.5
|
L
 329.5%
H
6.9
96.5
|
L
H
4.5
96.5
|
| Pulmatrix Inc |
|
8.3
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 -3.0%
H
2.2
2.4
|
L
 -46.8%
H
2.2
4.9
|
L
 -53.4%
H
2.2
5.5
|
L
 -68.5%
H
2.2
10.4
|
L
 -39.1%
H
1.6
10.4
|
L
 -91.0%
H
1.6
60.8
|
L
 -99.7%
H
1.6
1396
|
| Polypid Ltd |
|
74.4
|
4.5
|
L
 2.8%
H
4.3
4.5
|
L
 9.8%
H
4.0
4.6
|
L
 13.5%
H
3.9
4.6
|
L
 27.7%
H
3.1
4.6
|
L
 46.1%
H
2.3
4.6
|
L
 -78.7%
H
2.3
38.7
|
L
 -98.5%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
75.3
|
1.2
|
L
 5.2%
H
1.1
1.2
|
L
 9.0%
H
1.0
1.2
|
L
 -72.0%
H
1.0
4.6
|
L
 -52.9%
H
1.0
5.6
|
L
 -29.7%
H
0.8
5.6
|
L
 -12.9%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,171.1
|
16.8
|
L
 -1.9%
H
16.6
17.4
|
L
 -5.6%
H
16.6
17.7
|
L
 -3.1%
H
16.2
18.3
|
L
 4.2%
H
12.7
18.3
|
L
 70.0%
H
7.5
18.3
|
L
 46.0%
H
6.7
18.3
|
L
 12.7%
H
6.1
18.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
6.2
|
0.7
|
L
 4.6%
H
0.7
0.7
|
L
 -2.8%
H
0.6
0.7
|
L
 -18.8%
H
0.6
0.9
|
L
 17.0%
H
0.6
1.4
|
L
 -84.7%
H
0.5
4.6
|
L
 -97.5%
H
0.5
47.4
|
L
 -99.2%
H
0.5
145
|
L
 -99.9%
H
0.5
1390
|
| PureTech Health Plc ADR |
|
402.2
|
16.6
|
L
H
16.6
16.6
|
L
 -0.5%
H
16.6
17.0
|
L
 -0.9%
H
16.0
18.1
|
L
 -12.8%
H
15.5
19.0
|
L
 -11.5%
H
13.3
20
|
L
 -47.8%
H
13.3
38.5
|
L
 -70.5%
H
13.3
65.9
|
L
H
13.3
65.9
|
| AIxCrypto Holdings Inc |
|
13.7
|
2.7
|
L
 10.4%
H
2.5
2.8
|
L
 5.2%
H
2.2
2.8
|
L
 0.8%
H
2.2
3.0
|
L
 -49.3%
H
2.2
6.0
|
L
 -41.6%
H
1.6
8.8
|
L
 -96.1%
H
0.1
96.5
|
L
 -99.8%
H
0.1
2217
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
698.2
|
3.5
|
L
 -2.8%
H
3.3
3.6
|
L
 -19.1%
H
3.3
4.2
|
L
 -52.7%
H
3.3
7.4
|
L
 -63.6%
H
3.3
10.4
|
L
 -62.9%
H
3.3
17.2
|
L
 -18.1%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
| Quince Therapeutics Inc |
|
159.2
|
2.9
|
L
 -4.7%
H
2.9
3.1
|
L
 -19.7%
H
2.9
3.6
|
L
 -20.6%
H
2.9
4.6
|
L
 73.3%
H
1.4
4.6
|
L
 46.7%
H
0.7
4.6
|
L
 297.2%
H
0.5
4.6
|
L
 -90%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
1,409.7
|
22.6
|
L
 -3.3%
H
22.2
23.4
|
L
 -8.8%
H
22.2
24.8
|
L
 -0.5%
H
19.3
25.8
|
L
 -58.8%
H
19.3
71.5
|
L
 24.1%
H
7.8
71.5
|
L
 0.4%
H
3.7
71.5
|
L
 -38.4%
H
3.7
71.5
|
L
 43.1%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
11.8
|
14.1
|
L
 -0.2%
H
13.4
14.5
|
L
 0.4%
H
13.1
14.7
|
L
 -25.7%
H
9.7
15.5
|
L
 95.1%
H
7.2
41.8
|
L
 -97.2%
H
5.1
517.3
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
144.0
|
4.0
|
L
 -20.8%
H
3.8
5.1
|
L
 -39.8%
H
3.8
8.4
|
L
 -31.8%
H
3.8
8.5
|
L
 -18.0%
H
3.8
8.5
|
L
 227.3%
H
1.4
9.2
|
L
 -50.5%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
132.7
|
1.4
|
L
H
1.3
1.4
|
L
 -2.9%
H
1.3
1.4
|
L
 -13.4%
H
1.3
1.7
|
L
 172%
H
0.4
3.9
|
L
 -10.5%
H
0.4
3.9
|
L
 -77.9%
H
0.4
8.8
|
L
 -99.4%
H
0.4
36.3
|
L
H
0.4
224.5
|
| RAPT Therapeutics Inc |
|
826.3
|
29.8
|
L
 -6.4%
H
29.8
32.7
|
L
 -15.8%
H
29.8
36.3
|
L
 -13.5%
H
29.8
38.5
|
L
 -1.1%
H
24.3
42.4
|
L
 123.2%
H
5.7
42.4
|
L
 -83.0%
H
5.7
251.6
|
L
 -81.6%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
2,229.6
|
23.1
|
L
 -2.1%
H
22.6
23.8
|
L
 -32.4%
H
18.4
24
|
L
 -36.8%
H
18.4
39.9
|
L
 -26.0%
H
18.4
39.9
|
L
 -44.3%
H
18.4
46.5
|
L
 -51.3%
H
18.4
60.4
|
L
 -83.1%
H
18.4
175
|
L
 -77.3%
H
18.4
179.7
|
| Rocket Pharmaceuticals Inc |
|
384.2
|
3.6
|
L
 2.6%
H
3.5
3.6
|
L
 2.0%
H
3.4
3.6
|
L
 3.8%
H
3.2
3.7
|
L
 12.7%
H
2.8
4.5
|
L
 -71.7%
H
2.2
13.3
|
L
 -81.8%
H
2.2
32.5
|
L
 -93.7%
H
2.2
67.5
|
L
 -92.3%
H
2.2
67.5
|
| Regeneron Pharma |
|
80,215.1
|
763.2
|
L
 -1.7%
H
753.2
772.0
|
L
 -2.8%
H
753.2
785.1
|
L
 5.6%
H
691.9
792.8
|
L
 27.2%
H
541
792.8
|
L
 6.5%
H
476.5
792.8
|
L
 5.1%
H
476.5
1211.2
|
L
 58.1%
H
441
1211.2
|
L
 47.8%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
660.5
|
8.4
|
L
 -5.4%
H
8.2
8.9
|
L
 -15.5%
H
8.2
10.1
|
L
 -20.0%
H
8.2
11.1
|
L
 78.0%
H
4.3
11.3
|
L
 -33.3%
H
2.7
14.8
|
L
 -67.9%
H
2.7
29.5
|
L
 -78.0%
H
2.7
46.6
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
5.0
|
0.8
|
L
 3.7%
H
0.8
0.8
|
L
 -2.3%
H
0.8
0.9
|
L
 -16%
H
0.8
1.2
|
L
 -44%
H
0.8
1.7
|
L
 -97.3%
H
0.7
33.6
|
L
 -100.0%
H
0.7
16405.2
|
L
 -100.0%
H
0.7
569016
|
L
H
0.7
569016
|
| Regencell Bioscience Holdings Ltd |
|
13,371.0
|
27.0
|
L
 31.7%
H
23.3
29.4
|
L
 27.8%
H
19.8
29.4
|
L
 69%
H
15.0
29.4
|
L
 58.1%
H
10.3
29.4
|
L
 19214.3%
H
0.1
83.6
|
L
 3604.1%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
9,537.9
|
169.4
|
L
 3.1%
H
164.5
170.7
|
L
 1.9%
H
161.4
170.7
|
L
 2.2%
H
156.0
170.7
|
L
 13.9%
H
139.4
174.0
|
L
 15.2%
H
103.0
182.5
|
L
 -0.9%
H
103.0
211.1
|
L
 -11.1%
H
103.0
327.3
|
L
 503.0%
H
20.1
327.3
|
| Regenxbio Inc |
|
678.3
|
13.4
|
L
 -1.3%
H
12.9
13.8
|
L
 -5.4%
H
12.9
14.7
|
L
 3.2%
H
12.6
15.4
|
L
 28.5%
H
10.2
15.4
|
L
 72.5%
H
5.0
15.4
|
L
 -41.3%
H
5.0
28.8
|
L
 -70.2%
H
5.0
50.3
|
L
 -21.2%
H
5.0
85.1
|
| Rigel Pharma |
|
747.7
|
41.2
|
L
 -1.5%
H
40.5
42.7
|
L
 -6.4%
H
40.5
44.0
|
L
 -13.1%
H
39.6
50.0
|
L
 44.3%
H
26.4
52.2
|
L
 137%
H
15.5
52.2
|
L
 2951.1%
H
0.7
52.2
|
L
 1087.0%
H
0.6
52.2
|
L
 1340.2%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
1,362.3
|
7.9
|
L
 -3.9%
H
7.7
8.3
|
L
 -8.2%
H
7.7
8.6
|
L
 -1.8%
H
7.4
9.0
|
L
 43.4%
H
5.5
9.0
|
L
 81.9%
H
1.8
9.0
|
L
 -50.8%
H
1.8
23.2
|
L
 -80.6%
H
1.8
64.4
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
310.2
|
4.2
|
L
 -3.2%
H
4.0
4.5
|
L
 -6.2%
H
4.0
5.0
|
L
 5.8%
H
4.0
5.0
|
L
 82.3%
H
1.8
5.1
|
L
 800%
H
0.2
5.1
|
L
 23.0%
H
0.2
7.2
|
L
 -87.2%
H
0.2
40
|
L
 -57.7%
H
0.2
54
|
| Avidity Biosciences Inc |
|
10,859.2
|
72.1
|
L
 0.0%
H
72
72.2
|
L
 -0.1%
H
72
72.2
|
L
 0.7%
H
71.2
72.6
|
L
 53.3%
H
45.2
72.6
|
L
 136.3%
H
21.5
72.6
|
L
 265.8%
H
4.8
72.6
|
L
 183.0%
H
4.8
72.6
|
L
H
4.8
72.6
|
| TransCode Therapeutics Inc |
|
6.7
|
7.3
|
L
 -1.2%
H
7.0
7.9
|
L
 5.0%
H
6.1
7.9
|
L
 -15.4%
H
6.1
11.3
|
L
 -30.8%
H
6.1
21.0
|
L
 -92.8%
H
6.1
468.4
|
L
 -100.0%
H
6.1
790944
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| RenovoRx Inc |
|
34.8
|
1.0
|
L
 13.1%
H
0.9
1.0
|
L
 10.5%
H
0.8
1.0
|
L
H
0.8
1
|
L
 -28.0%
H
0.7
1.4
|
L
 -31.2%
H
0.7
1.7
|
L
 -64.8%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
14,814.0
|
21.3
|
L
 -2.9%
H
20.8
22.0
|
L
 -4.2%
H
20.8
22.3
|
L
 0.6%
H
20.1
23.5
|
L
 31.7%
H
15.3
23.5
|
L
 82.2%
H
8.7
23.5
|
L
 181.7%
H
6.6
23.5
|
L
 109.4%
H
2.5
23.5
|
L
H
2.5
23.5
|
| Royalty Pharma PLC (Class A) |
|
16,940.4
|
39.7
|
L
 2.0%
H
38.5
39.9
|
L
 1.1%
H
38.3
39.9
|
L
 1.3%
H
37.8
39.9
|
L
 9.9%
H
35.2
41.2
|
L
 53.4%
H
25.4
41.2
|
L
 1.3%
H
24.1
41.2
|
L
 -15.3%
H
24.1
53.2
|
L
H
24.1
56.5
|
| Repare Therapeutics Inc |
|
110.8
|
2.6
|
L
H
2.6
2.6
|
L
H
2.6
2.7
|
L
 15.3%
H
2.1
2.7
|
L
 42.8%
H
1.7
2.7
|
L
 84.9%
H
0.9
2.7
|
L
 -82.9%
H
0.9
15.3
|
L
 -92.9%
H
0.9
46.4
|
L
H
0.9
46.4
|
| Revolution Medicines Inc |
|
15,142.7
|
78.3
|
L
 -0.9%
H
76.3
78.9
|
L
 -3%
H
76.3
80.9
|
L
 -0.2%
H
73
82.0
|
L
 67.7%
H
45.8
82.0
|
L
 77.5%
H
29.2
82.0
|
L
 235.9%
H
15.5
82.0
|
L
 106.5%
H
14.1
82.0
|
L
H
14.1
82.0
|
| Reviva Pharma Holdings Inc |
|
38.6
|
0.3
|
L
 6.5%
H
0.3
0.3
|
L
 6.5%
H
0.3
0.3
|
L
 -44.1%
H
0.3
0.8
|
L
 -38.9%
H
0.3
0.9
|
L
 -83.7%
H
0.3
2.2
|
L
 -91.9%
H
0.3
9.3
|
L
 -96.3%
H
0.3
9.6
|
L
H
0.3
15.1
|
| Recursion Pharma Inc (Class A) |
|
2,274.4
|
4.4
|
L
 4.1%
H
4.3
4.4
|
L
 2.8%
H
4.1
4.4
|
L
 -11.2%
H
4.1
5.1
|
L
 -20.4%
H
3.8
7.2
|
L
 -44.0%
H
3.8
12.4
|
L
 -44.1%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharma Inc |
|
6,797.7
|
101.9
|
L
 -3%
H
99.5
104.7
|
L
 -7.4%
H
99.5
114.2
|
L
 -3.6%
H
99.5
122.2
|
L
 2.9%
H
95.3
122.2
|
L
 70.9%
H
45.9
122.2
|
L
 258.5%
H
15.5
122.2
|
L
 235.5%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
181.7
|
2.0
|
L
 -9.3%
H
1.9
2.2
|
L
 -26.6%
H
1.9
2.7
|
L
 -79.8%
H
1.1
11.2
|
L
 -78.5%
H
1.1
11.5
|
L
 -62.6%
H
1.1
11.5
|
L
 4.3%
H
0.7
11.5
|
L
 -84.6%
H
0.7
17.5
|
L
 -97.3%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
7.1
|
1.4
|
L
 35.9%
H
1.2
1.4
|
L
 22.8%
H
0.9
1.4
|
L
 16.7%
H
0.9
1.4
|
L
 -26.3%
H
0.9
2.2
|
L
 -78.5%
H
0.9
6.8
|
L
 -99.1%
H
0.9
287.5
|
L
 -100.0%
H
0.9
11520
|
L
 -100.0%
H
0.9
16540
|
| SAB Biotherapeutics Inc |
|
178.0
|
3.7
|
L
 -0.8%
H
3.6
3.8
|
L
 -1.1%
H
3.5
3.8
|
L
 -1.6%
H
3.3
4.1
|
L
 81.6%
H
2.1
4.2
|
L
 -3.9%
H
1
6.6
|
L
 523.3%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
1,081.4
|
4.1
|
L
 -3.1%
H
4.0
4.4
|
L
 -7.9%
H
3.9
4.4
|
L
 -21.6%
H
3.9
5.4
|
L
 2.5%
H
3.2
6.6
|
L
 132%
H
1.3
7.3
|
L
 1.0%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
101.4
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 -3.7%
H
2.0
2.2
|
L
 -36.8%
H
2.0
3.4
|
L
 -42.2%
H
2.0
5.0
|
L
 -28.8%
H
1.2
5.0
|
L
 -93.0%
H
1.2
42.2
|
L
 -70.4%
H
1.2
146.2
|
L
 -82.9%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
6.4
|
1.3
|
L
 2.3%
H
1.2
1.3
|
L
 4.0%
H
1.2
1.3
|
L
 -9.0%
H
1.2
1.5
|
L
 -14.4%
H
1.2
2.4
|
L
 -62.1%
H
1.2
3.9
|
L
 -98.2%
H
0.1
140
|
L
 -99.6%
H
0.1
6280
|
L
 -100.0%
H
0.1
300000
|
| Scilex Holding Co |
|
93.3
|
13.3
|
L
 1.3%
H
13.1
13.5
|
L
 -6.0%
H
11.8
14.2
|
L
 -31.7%
H
11.8
19.9
|
L
 -16.0%
H
11.8
27
|
L
 2782.6%
H
0.2
34.3
|
L
 172.8%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
26.9
|
0.6
|
L
H
0.6
0.7
|
L
 8.5%
H
0.6
0.7
|
L
 -4.5%
H
0.6
0.7
|
L
 -20%
H
0.6
0.9
|
L
 -51.5%
H
0.6
1.4
|
L
 -59.5%
H
0.6
3.9
|
L
 -91.1%
H
0.6
10.3
|
L
 -99.0%
H
0.6
66
|
| Seer Inc (Class A) |
|
103.5
|
1.8
|
L
 1.1%
H
1.8
1.8
|
L
H
1.8
1.9
|
L
 -4.2%
H
1.8
2.0
|
L
 -19.3%
H
1.8
2.4
|
L
 -22.4%
H
1.6
2.5
|
L
 -59.6%
H
1.5
6.2
|
L
 -96.6%
H
1.5
86.6
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,070.0
|
6.9
|
L
 2.2%
H
6.6
7.0
|
L
 3.4%
H
6.4
7.3
|
L
 0.1%
H
6.4
9.2
|
L
 -32.2%
H
6.0
10.5
|
L
 -32.7%
H
6.0
15.6
|
L
 -32.7%
H
6.0
15.6
|
L
 -32.7%
H
6.0
15.6
|
L
 -32.7%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
148.1
|
0.4
|
L
H
0.4
0.5
|
L
 4.8%
H
0.4
0.5
|
L
 -17.0%
H
0.4
0.5
|
L
 -35.3%
H
0.4
0.8
|
L
 -63.3%
H
0.4
1.5
|
L
 -86.7%
H
0.3
3.8
|
L
 -97.2%
H
0.3
17.5
|
L
 -95.1%
H
0.3
27.5
|
| Shuttle Pharma Holdings Inc |
|
3.9
|
2.0
|
L
 12.7%
H
1.9
2.1
|
L
 9.1%
H
1.6
2.4
|
L
 29.1%
H
1.4
2.4
|
L
 -54.5%
H
1.3
5.6
|
L
 -91.3%
H
1.3
25.3
|
L
 -99.4%
H
1.3
574
|
L
H
1.3
25252
|
L
H
1.3
25252
|
| SIGA Tech Inc |
|
457.6
|
6.4
|
L
 1.9%
H
6.3
6.5
|
L
 1.9%
H
6.1
6.5
|
L
 0.8%
H
6.1
6.5
|
L
 -28.6%
H
5.7
9.0
|
L
 1.0%
H
5.0
9.6
|
L
 -9.7%
H
4.2
12.8
|
L
 -12.0%
H
4.2
27.0
|
L
 914.3%
H
0.4
27.0
|
| SILO Pharma Inc |
|
4.7
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -2.8%
H
0.3
0.4
|
L
 -22.2%
H
0.3
0.5
|
L
 -50%
H
0.3
0.7
|
L
 -64.7%
H
0.3
3.4
|
L
 -87.5%
H
0.3
4.5
|
L
 -98.4%
H
0.3
496
|
L
 -99.4%
H
0.3
496
|
| Solid Biosciences Inc |
|
415.3
|
5.3
|
L
 -2.2%
H
5.2
5.5
|
L
 -8.7%
H
5.2
5.9
|
L
 -10.0%
H
5.2
6.2
|
L
 -9.7%
H
3.8
6.8
|
L
 28.7%
H
2.4
7.4
|
L
 -7.3%
H
1.8
15.1
|
L
 -95.5%
H
1.8
173.7
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
123.1
|
44.2
|
L
 4.8%
H
43
44.3
|
L
 5.6%
H
40.1
44.5
|
L
 8.6%
H
38.3
45.0
|
L
 27.0%
H
28.8
52.3
|
L
 3954.1%
H
0.4
52.3
|
L
 830.3%
H
0.3
52.3
|
L
 345.0%
H
0.3
52.3
|
L
H
0.3
52.3
|